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Health Care Productivity 
IN  ALL  OF  THE  INDUSTRIAL  COUNTRIES,  a high fraction of gross domestic 
product (GDP),  ranging  from approximately  7  percent in the United 
Kingdom to  14 percent in the United States,  is devoted to health care. 
In recent years policymakers  have been forced to try to trim health care 
benefits or other social  services,  and the health care systems  of almost 
all  the  industrial  countries  have  come  under  significant  pressure  to 
control expenditures  and improve performance. 
Although  each nation's  health care system  operates with a mixture 
of regulation and market mechanisms,  there are great differences  among 
them. And these differences  suggest that policymakers  could learn im- 
portant lessons  by comparing performances across countries.  Thus far, 
however,  no single  system  is recognized  as being the most productive 
or as having achieved the right blend of competition and regulation. No 
system provides the paradigm for others. 
Some observers of the U.S.  health care system argue that aggregate 
data indicate  poor  performance.  Figure  1 shows  aggregate  spending 
data for Germany, the United Kingdom,  and the United States; with the 
highest  level  of GDP and the largest fraction of  spending,  the United 
States spends much more per capita on health than the other two coun- 
tries.  Figure 2 provides  a simple aggregate performance measure.  Av- 
erage  life  expectancy  at birth in  the  United  States  is  lower  than in 
Germany and the United Kingdom,  although,  as the figure also shows, 
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Figure 1. Growth  in Health Care Spending  in the United States, United Kingdom,  and 
Germany 
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Source:  McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
Note: The purchasing  power parity  (PPP) exchange rates used in this figure  are for all of gross domestic product  (GDP), not for 
health care. The difficulties that confront international  price comparisons  for health services led us to conclude that the overall 
GDP PPP is a better  measure  of the real opportunity  cost of health  care spending  in the three  countries. 
higher infant mortality is the principal cause of the lower life expectancy 
in the United States.  Life  expectancy  for adults is more nearly equal. 
Even so,  with higher spending and outcomes  that are apparently worse 
or no better, it would be easy to conclude  that the health care delivery 
system  in the United States is unproductive relative to other countries. 
In fact the available aggregate evidence  does not establish the valid- 
ity of this conclusion.  Other factors,  such as differences  in lifestyles, 
diet,  and health practices,  differ among countries and can have major 
impacts  on  mortality.  Many  forms  of  disease  treatment improve  the 
quality of life even if they do not extend it. Moreover,  observed differ- 
ences  in mortality may be associated with differences  in access to care, 
rather than  with  differences  in  the  productivities  of  the  health  care Martin  Neil Baily and Alan M. Garber  145 
Figure 2. Life Expectancy  and Infant Mortality,  1990 
LIFE EXPECTANCY  INFANT  MORTALITY  LIFE EXPECTANCY 
AT BIRTH  PER  100  LIVE  BIRTHS  AT AGE 40 
Years  Years  Years 
U.S.  75.4  0.92  77.6 
U.K.  75.8  0.79  77.5 
Germany  75.8  0.71  77.9 
Source:  McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
delivery  systems  themselves.  Thus,  aggregate-level  evidence  does not 
reveal  whether the U.S.  health care system  is more costly  than other 
systems  because  Americans  pay health care providers more,  because 
productivity  is different,  or because  Americans  simply  demand more 
treatment. 
To gain a better understanding of this issue,  McKinsey and Company 
launched a project that had two major objectives: 
*  To assess  differences  in relative productivity  at the disease  level 
among  the health care systems  of  three industrialized  nations- 
the United  States,  Germany,  and the United Kingdom. 
*  To examine  the major causes  of these differences  by focusing  on 
variations  in  diagnostic  and  treatment  approaches  and relating 
such variations to provider incentives  and supply constraints that 
arise from the structure and regulations  of each country's  health 
care system. 
The project focused  on productivity,  not on the overall performance 
of the health care system. I Productivity,  a critical determinant of health 
1.  The working team consisted  of Lynn Dorsey,  Cuong Do,  Andrew Gengos,  Elise 146  Brookings  Papers:  Microeconomics  1997 
care system  performance,  can be defined  as the physical  inputs used 
(labor, capital, and supplies) to achieve a given level of health outcomes 
in treating a specific disease.  In other words, the concept of productivity 
can be applied to health care by viewing  the management or treatment 
of  a disease  as the fundamental  "production  process"  in health care. 
By  improving  productivity,  countries  can alleviate  spending  pressure 
on their systems  while maintaining the level  of outcomes,  or they may 
be able to improve outcomes  without increasing  spending. 
Four important qualifications to the scope of the project must be kept 
in mind.  First,  productive efficiency  does  not always  imply allocative 
efficiency;  one country can produce a great deal of health from limited 
resources,  demonstrating high productivity,  yet provide too little health 
care for its population  overall.  Conversely,  it might achieve  little  ad- 
ditional outcome  with the use of greater resources,  doing so with pro- 
ductive  efficiency  (that  is,  no  alternative  production  process  would 
result in the same level  of health with less resource use),  but producing 
more than the socially  optimal quantity.  Although  the project did not 
study this  important element  of  the policy  choice,  understanding the 
impact  of  economic  incentives  on  health  care productivity  can  help 
policymakers  understand any trade-off between allocative  and produc- 
tive efficiency  that may exist. 
Second,  the project focused on only four specific diseases-diabetes, 
cholelithiasis  (gallstones),  breast cancer,  and lung cancer-so  the ob- 
servations do not paint a complete  picture of the health care systems  in 
the three countries.  Nevertheless,  these  four conditions  are common, 
important, and representative. Thus we believe  many of the lessons  that 
emerge  from the cases  can be generalized. 
Third, the figures presented for inputs and outputs are national av- 
erages,  which  obscure the large variations that exist  within countries. 
In the United States,  for example,  health care can be reimbursed on an 
indemnity  (fee-for-service)  or on a capitated basis  (fixed  annual pay- 
ment  to  the  provider  organization  for  all  covered  services  for  each 
Russi, John Goree, Frank Basile,  Paul Brody, David Crawley, Alexis Dormandy, 
Thomas  Gertsner,  Nicolaus Henke, Dolores Heras, Michele Holcomb, Debbie Kelsey, 
Keiko  Kin, Karl  Krista,  Joan  Mehn,  Uma  Muthu,  Vikram  Narasimhan,  Sheryl  Sandberg, 
Mary  Ann Aitken, Julie Eskay, Diane Gutheil, Donna Gregory,  Ruby Kapadia.  Kathy 
Knauss, and Doreen Welborn. The Outside Advisory Committee included Kenneth 
Arrow, Axel Borsch Supan, and Ted Hall as well as the two authors  of this article. 
Bernard  Ferrari,  Bill Lewis, and  Charles  Schetter  oversaw  the completion  of this project. Martin  Neil Baily and Alan M. Garber  147 
enrollee),  or some blend of the two. The mix of capitation (or managed 
care) and traditional fee-for-service  care varies greatly around the coun- 
try. Just as the financing mix varies, so do clinical practices. Treatments 
vary by  city  and region.2  The  project team  was  well  aware of  these 
differences  but lacked the data necessary  to carry out a more disaggre- 
gated formal analysis.  Based on interviews  with health care practition- 
ers  in the three countries,  we  think that the country differences  that 
emerge in the cases are large and real and are representative of the three 
countries. 
Fourth, the case study data were drawn from the mid- to late 1980s. 
Since  then  the  health  care  systems  in  all  three countries  have  been 
changing; structural and regulatory reforms have occurred in the United 
Kingdom  and Germany,  and managed  care has  grown rapidly  in the 
United States.  Some of the patterns of care that we observed  may thus 
no longer be the norms in their respective  countries.  Conclusions  about 
the impact of  economic  incentives  on provider behavior  are likely  to 
remain valid,  however,  and many of  the  institutions  and regulations 
that influenced  patterns of care then remain in place today. 
Measurement and Assessment Issues 
Levels  of inputs used in each country, along with disease  outcomes, 
can be measured directly,  but these  are not in themselves  sufficient  to 
calculate relative productivity.  That is because the treatment of a given 
disease  is  fundamentally  a  diminishing  returns or,  to  state  it  more 
weakly,  a nonincreasing  returns activity.  For the disease  cases,  pro- 
duction can be considered  on a per-case or a per-patient-treated basis. 
When the quantity of health services  is increased,  it can be on one of 
two margins: greater resource intensity in the treatment of each patient, 
or an increase  in the number of  patients treated. Along  both of  these 
margins,  diminishing  returns are likely.3 
Along  the treatment-intensity  margin,  at least in the relevant range 
2.  The U.K. data  are for southern  England,  not the entire  country. 
3.  Ernst  Berndt  argued  that we are really talking about  returns  to scale, not dimin- 
ishing returns  to a single factor. We think, however, that  applying  incremental  doses of 
capital, labor, and supplies to a given disease population  is more intuitively  thought  of 
as a diminishing  returns  activity. The idea seems clear irrespective  of terminology. 148  Brookings  Papers: Microeconomics 1997 
of output, diminishing returns are likely to be the rule-most  conditions 
will  respond  to  additional  units of  treatment or resources  devoted  to 
diagnostic  and other management  with  successively  smaller  units  of 
health output. If patients who derive the greatest benefit from care are 
the first to receive  it, diminishing  returns are also likely to characterize 
an expansion  in the number of patients treated. In a system that effec- 
tively  "triages"  candidates for any specific treatment, the patients most 
likely to benefit from that treatment will receive care first, the next most 
likely  patients  second,  and so  on.  In the United  States,  this  form of 
triage is modified by the market, where those  with comprehensive  in- 
surance or the greatest willingness  to pay may be more likely to receive, 
say,  gallbladder surgery than those patients without explicit  coverage. 
But because most of the uninsured have some access to treatment in the 
United  States,  overall  there will  be diminishing  returns in the produc- 
tion of health care in all three countries. 
Diminishing  returns in medical treatments carry several implications. 
The country that devotes  more resources  to a disease  will  have lower 
average productivity than the other country.4 This is not a reflection of 
inefficiency,  but a condition inherent in diminishing returns production. 
To evaluate  productive efficiency,  one must consider  not only  how to 
measure  inputs  and outcomes,  but also  how  to  assess  the results.  A 
specific  definition  of  productive  efficiency  is thus needed  in order to 
rank outcomes. 
Estimating Inputs Used 
To estimate the inputs used, the McKinsey team developed a detailed 
model  of each disease  treatment process.  The model  incorporated the 
important steps in the process,  the key choices  and decisions  that pro- 
viders face  at each  step,  and the resulting  resource implications.  The 
sources  of data used to explain  the steps of the treatment process  and 
associated  inputs included  published  descriptions  in the medical  liter- 
ature, analyses  of national databases (such as hospital discharge infor- 
mation),  and interviews  with practitioners and administrators in each 
country. 
Physical inputs included labor (from physicians,  nurses, technicians, 
4.  This is the case for two countries  operating  on the same production  function. See 
the discussion of figure  4. Martin  Neil Baily and Alan M. Garber  149 
and other health care providers), supplies (such as medications,  surgical 
instruments, and X-ray film), and capital (such as diagnostic equipment 
and hospital facilities,  where data were available).  For the labor inputs 
associated  with an inpatient stay, we used a simplified model that mul- 
tiplied each country's  average staffing level  per day of hospital stay by 
the average length of stay for treating the specific disease.  Because  the 
units  of  measurement  for  each  input vary,  inputs  were  standardized 
using  a base unit cost,  which  was an hour of a surgeon's  time.  (Note 
that the choice  of  the base  unit is  arbitrary and has no effect  on the 
results.)  We then calculated  the weighted  sum of  the labor,  supplies, 
and capital used to obtain an aggregate measure of physical  inputs for 
each  disease  treatment process  in each  country.  More  detail  on  our 
input methodology  is given  in the final report of the project.5 
Administrative  Costs 
Omitted  from  the  case  analysis  is  any  estimate  of  administrative 
costs.  We are focusing  on the inputs used to treat the diseases,  not on 
the health care systems  in total. This issue  is addressed explicitly  later 
in the paper when  the case  results  are related to the aggregate  data. 
Administrative costs are estimated to be about 24 percent of total spend- 
ing in the United States,  13 percent in Germany, and 16 percent in the 
United Kingdom. 
Estimating  Outcomes 
Outcome  measures pertinent to each disease  were adjusted for dif- 
ferences in disease incidence  across countries. Like the input measures, 
outcome measures were derived from literature reviews,  database anal- 
yses,  and interviews  with  clinical  experts.  We  derived  our outcome 
measures by comparing the expected health outcomes  with treatment in 
each country to the outcomes  without treatment, which are presumably 
similar  in each  country.  An example  using  mortality as the outcome 
measure is shown in figure 3. Because  the outcome represents a change 
in health status,  it is necessary  to quantify health status expected  for 
each disease  and to estimate the improvement in health that results from 
the disease  treatment process. 
5.  McKinsey  Global  Institute and the McKinsey  Health Care Practice (1996). 150  Brookings  Papers:  Microeconomics  1997 
Figure  3. Survival  Curves with and without  Treatment 
Per case 
Percentage of survivors 
100 
With  treatment 
Without 
treatment 
Time after diagnosis 
Source:  Authors'  conceptualization. 
QUANTIFYING  HEALTH.  Outcomes  for each disease  can be quantified 
using either survival rates or calculations  modeling  the quality of life. 
Survival rates are relatively easy to assess and are appropriate measures 
for lung and breast cancers,  in which  the primary goal of treatment is 
to reduce the high level of mortality. Outcomes for the cancers can thus 
be measured as years of life expectancy or life years (LYs).  For diabetes 
and cholelithiasis,  whose  mortality rates are much lower,  the primary 
treatment goal  is to reduce the incidence  and severity  of  disabling  or 
painful but nonfatal complications  of the disease.  Because  treatment is 
intended to improve the quality of life-not  only its duration-survival 
is  an inadequate  measure  of  health outcomes  for these  diseases.  For 
these diseases,  we used the Kaplan-Bush  Index of Well-Being  to cal- 
culate  outcomes  in quality-adjusted  life  years  (QALYs).  We  believe 
that our  major findings  would  have  been  similar  if  we  had  applied Martin  Neil Bailv and Alan M. Garber  151 
another method for quantifying quality-of-life  effects.  Although quality 
of  life  is  also  relevant  in the cancers,  it is  quite difficult  to measure 
with  available  data and accounts  for  less  of  the  intended benefits  of 
treatment. 
MEASURING  IMPROVEMENT  IN  HEALTH  FROM  TREATMENT.  Outcomes 
without  treatment are usually  unknown  and can be influenced  by the 
patient's baseline  health status, which in turn reflects lifestyle,  cultural 
factors, genetics,  and so on. For some of the disease cases,  we assumed 
that the baseline or untreated health outcome would be the same in each 
country,  so that the absolute levels  of health in treated patients would 
be a valid basis for comparing the outcomes  of treatment in each coun- 
try. Although available data are not conclusive,  they are consistent with 
this assumption.  Our studies were modified for situations in which this 
assumption  might  not have  been  valid;  for example,  in the  diabetes 
case,  we  compared  the outcome  for the United  Kingdom  to  that for 
U.S.  whites  because  nonwhites  are known to have higher rates of dia- 
betes and of diabetic  complications  than whites. 
Baseline  health  status was  estimated  for some  diseases  in order to 
calculate  the change in outcomes  with treatment. As mentioned earlier 
and described  in greater detail  later,  we  used this approach to assess 
relative  productive  efficiency  in  those  cases  in  which  one  country 
achieved  better outcomes  using more inputs. 
Determining  Levels of Productive  Efficiency 
We  defined  productive  efficiency  by  the  relative  positions  of  the 
health production functions for each country. Because we observed only 
one  point  for each  country for each  case,  we  could  not trace out the 
shapes of the production functions.  Yet the assumption of diminishing 
returns and the observations  of  inputs and outcomes  in each  country 
enabled  us to draw inferences  about relative  productive  efficiency  in 
most cases.6 
The simplest  case  for our comparisons  is illustrated by Countries A 
and B  in  figure 4:  Country  A  achieves  better outcomes  while  using 
fewer inputs,  so Country A must be more productive.  Countries A and 
C depict the more common  situation,  in which one country uses  more 
6.  Ernst Berndt points out that our assumption  is stronger than we need.  As long as 
there are not increasing  returns to scale,  our cross-country  conclusions  go through. 152  Brookings  Papers:  Microeconomics  1997 
Figure 4. Assessing  Productive  Efficiency 
Per case 
Outcomes 
/  ~~~Country  A 
///C  u  n  tr  y~  ~  ~~~~~~  Country B 
{  '  ~~~~Country  C  ,- 
Inputs 
Comparison  1: A vs. B  Comparison  3: C vs. D 
* A is more productive because it achieves  * C has higher inputs and outcomes but 
better or equal outcomes with less inputs  lower average productivity; productive 
Comparison  2: A vs. C  efficiency can only be determined based 
* A is more productive because it has  on detailed knowledge of treatment 
higher average productivity (ratio of  process 
outcomes to inputs) and treatment  Comparison  4: B vs. C 
process does not show increasing returns  *  No apparent  difference in relative pro- 
with additional care inputs  ductive efficiency; one country may 
have preferred input/outcome combina- 
tion based on cost-effectiveness  analysis 
Source:  Authors'  conceptualization. Martin  Neil Bailv anid  Alan M. Garber  153 
resources and has better outcomes than another. In the situation shown, 
Country A  has better outcomes  than Country C  and greater average 
productivity.  This  means  that,  with  diminishing  returns everywhere, 
Country A must be on a higher production function,  and so it has greater 
productive efficiency. 
Note  that this is a pure productive  efficiency  comparison  and does 
not represent a judgment about allocative  efficiency.  Without putting a 
value on the outcomes,  we cannot state that Country C would  choose 
the outcome-input  combination  in Country A rather than the combina- 
tion it currently has. But because the production function of Country A 
lies  above  the production  function  for Country C,  we  can argue that 
Country C has the potential to improve its productivity.  By operating 
on the same production function  as Country A,  Country C could have 
had better  outcomes  with  no  more  inputs.  If  there  were  increasing 
returns,  points  A  and C could  be  on  the  same  production  function. 
Without further information,  we could not infer that Country C would 
have potential  for improvement unless  it was willing  to raise its input 
level. 
The third type of comparison is illustrated by points C and D, where 
Country D appears to be on a higher production function.  Without more 
information,  however,  that conclusion  cannot be drawn with certainty. 
The lower  average productivity  in Country C may reflect either lower 
overall productive efficiency  or the result of market demand that caused 
production to operate at a portion of the production function with small 
marginal returns to  additional  inputs,  in order to  achieve  better out- 
comes.  The fourth type of comparison is between Country B and Coun- 
try C. As shown in figure 4,  these are on the same production function 
and hence have the same productive efficiency.  But again, because  we 
do not know the shape of the production function,  in practice we cannot 
tell this case  from the third type. 
Cost-Effectiveness  Analysis 
The inability to rank the third and fourth types of comparisons  does 
not preclude drawing conclusions  about their relative desirability.  The 
literature contains  rules of thumb for "reasonable"  cost-effectiveness 
ratios, although the cutoffs  are inherently arbitrary. Typical practice is 
to consider  interventions that cost less than $30,000  (1990  dollars) per 154  Brookings  Papers. Microeconomics  1997 
QALY  to  be  cost  effective,  to  consider  those  that  cost  more  than 
$100,000  per QALY as cost ineffective,  and to treat intermediate costs 
per QALY as a "gray area.  "7  Comparisons based on cost-effectiveness 
analysis  are not as clear-cut  for the productivity  analysis.  Fortunately 
it turns out that in all but one case,  we can compare productivity without 
needing  to resort to cost-effectiveness  comparisons.  But we  do report 
cost effectiveness  for the one case. 
We  turn now  to  a brief  discussion  of  each  of  the  four  diseases, 
describing  how they are treated and what we found in terms of inputs, 
outcomes,  and productive  efficiency.  In  these  summaries  we  try to 
explain the productivity differences  in terms of provider behavior. What 
are the doctors and hospitals  doing  that is different in the three coun- 
tries? Later in the paper, we consider how the economic  incentives  and 
system  constraints give  rise to these behavioral differences. 
Case  Study  Findings:  Diabetes 
Diabetes  mellitus  is a chronic condition  that impairs or destroys the 
body's  ability to regulate glucose  levels.  It affects a significant fraction 
of the population-about  2 to 3 percent-in  the United States and the 
United Kingdom and accounts for at least 4 to 6 percent of total health 
care costs  in both countries.8  (Because  information was  not available 
on treatment in Germany, we excluded it from this disease comparison.) 
Diabetes  mellitus  is really two different conditions.9 Type I, "juvenile 
onset"  diabetes,  occurs early in life  and destroys the body's  ability to 
produce insulin and therefore regulate glucose.  Type II, "adult onset" 
diabetes,  develops  later in life  and results  in insulin  secretion  that is 
insufficient  for the body's  needs,  in part because  sensitivity  to insulin 
is diminished.  Type II is the more common of the two,  accounting  for 
approximately  90  percent of  diabetics  in the two  countries.  Although 
they are different diseases  and can be treated differently,  many aspects 
of their treatment are similar and use the same providers. 
7.  Attempts  to  estimate  "optimal"  cost-effectiveness  ratios  based  on  a  specific 
family of utility functions suggest that double annual income is a reasonable cutoff under 
plausible  circumstances.  See Garber and Phelps (1997). 
8.  British Diabetic  Association  (1996);  National  Diabetes  Data Group (1995). 
9.  Our study  excluded  gestational  diabetes,  which  is  diabetes  with  onset  (or  first 
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There  is  no  cure  for  diabetes.  Instead,  early,  basic  treatment of 
diabetes is directed toward maintaining blood glucose  levels  in a near- 
normal range. For all Type I and many Type  II  diabetics,  regular insulin 
injections  are required. For some Type  II diabetics,  management con- 
sists primarily of controlling  the patient's diet and exercise  habits and, 
often,  taking oral medications  that control blood glucose  levels.  Once 
a patient is diagnosed  with the disease,  some form of diabetes manage- 
ment is needed for the rest of the patient's  life. 
Complications  of  diabetes  are frequent,  can significantly  diminish 
quality  of  life,  and can  even  be  life  threatening  or  fatal.  Common 
complications  include  heart and kidney  disease;  visual  impairment, 
which  may lead to blindness;  and foot  ulceration,  which  may require 
amputation. Effective  management of the diabetic's  condition  can sig- 
nificantly delay or prevent some of these complications. 
Inputs 
Patients themselves  provide the most important labor input into the 
treatment of diabetes in the form of self-care.  Self-care includes insulin 
injections,  self-testing  of blood and urine, and diet and exercise control. 
Although  the patient's  labor in performing these functions  is an input 
into the production process,  we  did not attempt to measure it for this 
analysis. 
As our omission  of Germany from this category demonstrates,  there 
is  a paucity  of  accurate data on capital  and supply  usage  in diabetes 
treatment. Almost all treatment directed toward continuing management 
of  the  disease  is  delivered  in  the  outpatient  setting,  where  data  are 
typically  unavailable.  Because  labor represents roughly 70 percent of 
the total cost  of  health care in both the United  States  and the United 
Kingdom,  we  believe  that it is an acceptable  simplification  to restrict 
our analysis  only  to the labor inputs required in treatment.  Although 
the cost of supplies for self-care,  particularly insulin, can be significant, 
the largest cost  component  of diabetes  is the inpatient care associated 
with  treating complications.  Labor is  clearly  the major input for  in- 
patient care. 
The diabetes  treatment steps  requiring the most  provider labor are 
the routine visits to manage the disease  and inpatient treatment of com- 
plications.  Our analysis  estimated  the labor inputs into both of  these 156  Brookings  Papers: Microeconomnics  1997 
treatment steps.  We  did not  include  costs  of  initial  diagnosis  in our 
measurements  because  these  diagnostic  tests  are usually  inexpensive 
and do  not  appear to  vary  significantly  between  the  two  countries. 
Neither country had a formal screening  program for diabetes.  Nor did 
we include outpatient visits to specialists  and tests beyond those handled 
in routine clinic  visits  (although such referrals are routinely performed 
to check for complications).  We focused only on the inpatient treatment 
generated by those referrals. Follow-up  visits  to specialists  after inpa- 
tient treatment were also excluded  from the measurement. 
Measurement of Outcomes 
Although  diabetes  cannot be cured,  treatment can prolong  life  and 
improve  its quality.  Because  complications  are chiefly  responsible  for 
both the morbidity and mortality of the disease,  we focused our analysis 
of outcomes  on the relative rates of developing  selected  complications 
in the two countries.  All other factors being equal, a health care system 
delivers  better outcomes  in  diabetes  by  preventing  and successfully 
managing  diabetic  complications. 
We  estimated  complication  rates by using  national databases,  sur- 
veys,  and the available medical literature. 10  Specifically,  we evaluated 
complication  rates for diabetic ketoacidosis  and hyperosmolar coma (a 
pair of  similar  complications  that often  occur  in association  with  an 
acute illness  such as kidney or lung infection),  retinopathy (abnormal- 
ities  of  the retina that can lead to progressive  visual  loss),  blindness, 
and lower extremity  amputation.  For each of these complications,  we 
were able to obtain comparable estimates  of the incidence  rate in both 
countries. "  I 
To develop  an overall  measure of outcomes  for diabetes treatment, 
we estimated the impact of each complication  on a diabetic's  quality of 
life.  When quality of  life  is incorporated into cost-effectiveness  anal- 
yses,  a weighting  or utility is assigned to each state,  so that a value of 
one  is  equivalent  to  best  imaginable  health,  and a  value  of  zero  is 
assigned  to the worst imaginable state, which is usually assumed to be 
10.  McKinsey  Global  Institute and the McKinsey  Health Care Practice (1996,  ap- 
pendix). 
11.  The two rates may not have been precisely  comparable,  because  the definitions 
of  complications  may  not  have  been  identical.  Furthermore,  the  average  duration of 
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equivalent to death. Kaplan and Bush devised a method to assign utility 
ratings  to  a  large  number of  health  states,  based  on  interviews  and 
surveys where population  samples expressed their relative preferences 
for these  health states.  Their health state ratings were comprehensive 
enough  to  allow  us  to  assign  utility  scores  to  each  state  of  diabetic 
complications.  Using  these  scores  and the incidence  rates for compli- 
cations,  we  developed  an "expected  quality-of-life  score"  for an av- 
erage diabetic in each country. (In essence,  this expected value weights 
a  complication's  effect  on  the  quality  of  life  by  the  probability  of 
developing  the complication.)  This expected  value,  which we used as 
our basic outcome  measure for diabetes,  is expressed  in QALYs. 
To derive an expected  QALY score for each country, we made sev- 
eral assumptions  about a diabetic's  potential  health states,  the quality 
scores of these states,  and the probabilities of being in these states over 
time. Although some of these specific assumptions could be challenged, 
and other models of expected QALY could be developed,  the final result 
of our outcome  comparison  is unlikely  to be sensitive  to the particular 
utility  assessment  method used.  Essentially,  any reasonable  set of as- 
sumptions and methodology  yields  an outcome measure that shows the 
United Kingdom having superior outcomes  for diabetes treatment, be- 
cause diabetics  there are less  likely  than diabetics  in the United States 
to develop  each of the complications. 
PRODUCTIVE  EFFICIENCY  DIFFERENCES.  On a weighted  average basis, 
the  United  Kingdom  used  34  percent  fewer  inputs  than the  United 
States,  and U.K.  diabetics  had  1.35  more QALYS.'2  Compared with 
the baseline  case  of no treatment, U.K.  diabetics  achieved  27 percent 
greater improvement in outcomes  due to treatment than U.S.  diabetics 
did. 1  3 
With  better outcomes  and fewer  inputs,  the United  Kingdom  was 
clearly  more productive  than the United  States  in diabetes  treatment. 
Its productive efficiency  advantage stemmed from its consistently  lower 
complication  rates.  Although  these  rates were  relatively  low  in both 
12.  Input usage was 40 percent less for Type I diabetics and 32 percent less for Type 
II diabetics.  Type I diabetics  in the United Kingdom had 2.5  more QALYs than diabetics 
in the United States; Type  II had 1.2 more. 
13.  Baseline  outcome  with  no  treatment was  conservatively  assumed  to  be  death 
within one year for Type  I diabetics;  Type  II diabetics  were assumed to have the same 
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countries  (roughly  1 to  3  percent  for  most  complications),  the  total 
impact of these annual rates during a diabetic's  lifetime  created a sig- 
nificant difference  in overall outcomes.  The United Kingdom's  advan- 
tage for Type I diabetes outcomes  was greater, primarily because  that 
type occurs  at a younger  age,  so the United  Kingdom's  advantage in 
complication  rates compounded  over a larger number of years. 
REASONS  FOR  THE  DIFFERENCES.  The lower rate of complications  ap- 
peared to derive  from two  aspects  of  provider behavior in the United 
Kingdom:  more  intense  treatment for  those  who  could  benefit  most 
(stricter triaging),  and a team-based approach. Although the effect each 
of these  factors had on complication  rate differences  between  the two 
countries cannot be quantified,  according to interviews  with clinicians 
in the two countries,  both seemed  to be important. 
In contrast to the more uniform approach to the treatment of diabetes 
in the United  States,  the United  Kingdom  was  highly  selective  in as- 
signing aggressive  treatments. For some diabetics,  generally those con- 
sidered to have the least  severe  conditions,  the United Kingdom  pro- 
vided  less  treatment than the United  States;  more than 40  percent of 
noninsulin-using  Type II diabetics in the United Kingdom received only 
home care,  whereas 93 percent of these diabetics  in the United States 
were treated by a physician.  For the two-thirds of diabetics in the United 
Kingdom  who  received  some  form of  physician-guided  care,  routine 
visits  with providers occurred about five times  a year,  compared with 
an average of  3.5  visits  a year in the United  States.  For the one-third 
of U.K.  diabetics  seen in a diabetic clinic,  visits  were also more com- 
prehensive  than comparable  visits  in the  United  States.  The  United 
Kingdom thus provided more intensive  treatment to the diabetics  with 
the most severe conditions.  The United Kingdom's  diabetic clinics  not 
only offered  more provider attention to certain diabetics,  but they also 
offered  care from many different types of providers in a multidiscipli- 
nary team that might have included a diabetologist,  an ophthalmologist, 
a chiropodist,  a dietician,  and a nurse specialized  in diabetes. This team 
likely  was more effective  than a single  physician  in assessing  the dia- 
betic's  condition,  developing  a self-care  program, and educating  and 
counseling  the diabetic. 14 
14.  The United  Kingdom's  better outcomes  for diabetes  could  also  have been  par- 
tially  caused  by  behavioral  differences  between  U.K.  and U.S.  patients;  if  the  U.K. Martin  Neil Bailv and Alan M. Garber  159 
Cholelithiasis (Gallstones) 
Cholelithiasis,  or the presence  of  stones  in the gallbladder,  is very 
common  in Western nations.  Approximately  11 percent of the popula- 
tion of the United States,  the United Kingdom,  and Germany, totaling 
more than 42 million  people,  have cholelithiasis.  Nearly 2 million  new 
cases  are diagnosed  in these countries each year. 15 Although gallstones 
can cause abdominal pain and other symptoms,  most of them are asymp- 
tomatic.  Only  1 to 4 percent of patients with gallstones  develop  symp- 
toms or complications  each year; 10 percent of all patients with chole- 
lithiasis  develop  symptoms  five years after diagnosis,  and 20  percent 
develop  symptoms  after twenty years.  Even though serious complica- 
tions of cholelithiasis  are infrequent, a great deal of effort and resources 
are spent  in treating this condition,  amounting to  about $7  billion  in 
1992  in the three countries.  Consequently,  cholelithiasis  is one of the 
costliest,  as well  as most common,  digestive  diseases. 
Although  gallstones  can lead to life-threatening  conditions  such as 
acute cholecystitis,  6  the most common  symptom,  abdominal pain,  is 
usually mild,  is often transient, and is not unique to cholelithiasis.  The 
most common  method for removing  gallstones  is cholecystectomy,  or 
surgical removal of the gallbladder with its contents.  Two  approaches 
to cholecystectomy  are now  common:  traditional,  or open,  cholecys- 
tectomy;  and laparoscopic  cholecystectomy.  Surgical  removal  is usu- 
diabetics  were  "better"  patients (patients who take better care of their conditions),  that 
could  have  led  to  the  lower  complication  rates  observed.  Access  issues  could  have 
contributed to worse overall outcomes  in the United States; if a group of U.S.  diabetics 
did  not have  access  to  care and,  therefore,  had poor outcomes,  the  population-based 
complication  rates could have been driven up significantly.  Because  no national data are 
available  to  compare  treatment compliance  in the  two  populations  or to  evaluate  the 
impact of uneven  access  to care in the United  States,  we  were unable to determine the 
role  these  factors  might  have  played  in the relative  complication  rates.  Additionally, 
higher levels  of obesity  in the United States could partially explain  higher complication 
rates there for Type  II diabetics; Type  I diabetics,  who are generally  younger and not as 
subject to obesity,  would  be unaffected  by this difference. 
15.  Graves (1995);  National Health Service  (1995a,  b); Kramling and others (1993). 
16.  Additional  potentially  life-threatening  conditions  include empyema  of the gall- 
bladder, common  bile  duct stones  with or without cholangitis  or pancreatitis,  gallstone 
ileus,  or,  rarely,  gallbladder  cancer.  Life-threatening  gallstone  complications  almost 
always  merit acute care,  but these  are uncommon.  In addition,  the risk of  gallbladder 
cancer in patients with gallstones  is very low (currently estimated at 1 of  1,000  patients 
a year).  This cancer risk,  therefore,  does  not ordinarily justify  prophylactic treatment. 160  Brookings  Papers: Microeconomics  1997 
ally recommended on the basis of the severity  and frequency of symp- 
toms,  the presence  of coexisting  diseases,  and the risk that the patient 
will  suffer  complications  from the procedure.  Cholecystectomies  are 
relatively  free of complications,  however,  and nonsurgical alternatives 
are  less  effective  at  preventing  recurrence  of  symptoms.  Thus,  the 
safety  and efficacy  of surgery have made it the treatment of choice  for 
symptomatic  cholelithiasis. 
Management and Treatment 
We evaluated relative productive efficiency  using two measures: out- 
comes  per unit of inputs on a per-operation basis (that is,  productivity 
when a cholecystectomy  was performed) and on a per-case (per patient 
with cholelithiasis)  basis. The per-operation results highlighted the dif- 
ferences  in resource allocation  per operation; the per-case results mea- 
sured the overall input usage when treating the disease  in each country. 
A  country  that was  not  particularly  efficient  in  the  performance  of 
surgery could  have  high productive  efficiency  on a per-case  basis  by 
assigning  patients to surgery in a highly  selective  manner. 
We divided  the management of cholelithiasis  into three phases: di- 
agnosis,  treatment, and recovery.  In the diagnosis  phase,  patients and 
physicians  decide  whether and how to treat. If surgery is selected,  the 
patient receives  pre- and postoperative  tests,  the operation itself,  and 
any additional procedures required to treat complications.  Finally,  each 
patient  enters  a period  of  convalescence,  primarily at home,  before 
resuming work and other usual activities. 
Inputs 
We accounted for the actual use of labor, supplies,  and capital in the 
treatment. Because  recovery time is a significant component of the cost 
of treating cholelithiasis,  we  also included the opportunity cost of pa- 
tient time, measured by weighting  the number of work hours the patient 
spent in the hospital  and during recovery  by the average hourly wage 
in the country.  We  summed  the per-operation use  of  labor,  supplies, 
and capital separately for the open and laparoscopic operations in each 
country and used the relative number of each to obtain weighted  inputs. 
Adding  together  these  weighted  inputs,  we  obtained  the  total  input 
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The input total per case  is simply  the input total per operation mul- 
tiplied  by  the  surgical  frequency  per case.  Surgical  frequency  is  the 
percentage of  cholecystectomies  per capita divided  by the prevalence 
of  cholelithiasis  in the same  country.  Unless  specified  otherwise,  we 
discuss  results on a per-case basis. 
To the extent possible,  the analysis  incorporates the inputs used  in 
each  step of  surgical  treatment,  including  the treatment of  complica- 
tions,  common  bile duct exploration,  and stone removal.  The analysis 
did not include nonsurgical treatments, which were rarely used, nor did 
it incorporate diagnostic  tests  and analgesia  for patients who  did not 
receive  further treatment. These  costs  are likely  to be very  low,  and 
accurate estimates  are unavailable. 
Outcomes 
These  outcomes  reflect both the long-term  effectiveness  of  the op- 
eration  and operative  morbidity  and mortality.  Significant  complica- 
tions  from  these  operations  were  infrequent  and similar  in  all  three 
countries:  3.0  to 5.0  percent for open cholecystectomy;  and 3.5  to 4.4 
percent for the laparoscopic operation. 17 Because  both surgical options 
had similarly  high success  rates,  it is reasonable to presume that each 
country produced similar outcomes  per operation. 
Outcomes per case were somewhat more complex.  The relative suc- 
cess  of  cholelithiasis  treatment depended  crucially  on the decision  to 
proceed with surgery.  Both the potential benefit from surgery and the 
success  of  each  individual  operation  affected  the  per-case  outcome. 
Ideally,  both of these  factors would  be incorporated into the outcome 
measure to assess  the overall quality of treatment. Although the degree 
of surgical success  was approximately equal in the three countries,  the 
potential benefit to the patient who underwent surgery depended on the 
severity  of symptoms. 
We incorporated symptom relief  into our model of health outcomes 
by estimating the effects  of surgery on each patient's QALYs.  Pain was 
the major symptom,  and each pain episode reduced the patient's quality 
of life.  Thus,  before and during surgery, a patient's quality index was 
less than 1, and after surgery, the patient was restored to a quality index 
17.  Maclntyre  and  Wilson  (1993);  Roslyn  and  others  (1993);  Dunn  and  others 
(1994);  National  Center for Health Statistics  (1995). 162  Brookings  Papers: Microeconomics  1997 
of unity.  Outcomes  differed depending on the extent to which surgery 
alleviated  severe symptomatic disease  or treated disease that only mar- 
ginally  detracted from quality of life.  Because  the frequency of symp- 
tomatic  pain  episodes  varies  from  patient  to  patient,  we  calculated 
outcomes  using  a range of  frequency  of  symptoms,  from recurrence 
every  fourteen  days to recurrence every  sixty  days; when  choosing  a 
single  point  estimate,  we  assumed  that symptoms  occur  every  thirty 
days.  8 
Productive  Efficiency:  U.K. -U.S.  Comparison 
On a per-operation  basis,  the United States and the United Kingdom 
had  similar  outcomes,  but the  United  States  used  71  percent  fewer 
inputs. It used fewer resources per operation than the United Kingdom 
for both open and laparoscopic  operations,  and a higher proportion of 
the U.S.  operations were laparoscopic.  '9 
Although  it used fewer  inputs per operation,  the United States per- 
formed more operations.  Thus,  on a per-case  basis,  it used 56 percent 
more  inputs  than the  United  Kingdom.  This  higher  rate of  surgery 
yielded  outcomes  that were 76 percent better than those  in the United 
Kingdom  on  a per-case  basis.  Because  its  improvement  in outcomes 
was  greater than its  increase  in inputs,  the  United  States  had higher 
average productivity  than the United  Kingdom,  an advantage that did 
not  vary with  the  frequency  of  symptoms.  For example,  at fourteen 
days between  symptoms,  the United States was 72 percent higher than 
the United Kingdom; at sixty  days,  it was 76 percent higher. 
Productive  Efficiency.  German-U.S.  Comparison 
On a per-operation  basis,  the United  States  used  52  percent fewer 
resources than Germany while obtaining similar outcomes.  Even though 
Germany used  8 percent fewer  inputs per open  cholecystectomy,  the 
resource use per operation was lower in the United States, both because 
a greater percentage  of procedures were laparoscopic  and because  the 
United  States used about 40  percent fewer  resources  per laparoscopic 
18.  Clinician  interviews. 
19.  Inputs per laparoscopic  cholecystectomy  are indexed  to the U.S.  open  surgery 
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cholecystectomy.  Because  outcomes  per operation  were  equal,  the 
United  States was  more productive  in the laparoscopic  technique  and 
on an overall  per-operation basis. 
Because  Americans with cholelithiasis  were less likely to receive  an 
operation and because  the United  States used fewer  inputs per opera- 
tion,  the United States consumed  lower inputs per case  and had lower 
outcomes  on a per-case  basis  relative to Germany.  The United  States 
had  52  percent  higher  average  productivity  than Germany  over  the 
entire range of symptoms  occurring between  fourteen and sixty  days. 
In this  situation,  in which  the country with  the lower  input-lower 
outcome  combination  (that is,  the United States) was the country with 
higher average productivity,  we need detailed knowledge  of the treat- 
ment process to determine which country was more productive.  Shorter 
hospital stays,  shorter recovery periods,  and broader adoption of lapa- 
roscopy  enabled  the United  States to use 72  percent fewer  inputs per 
operation,  with  identical  surgical  outcomes.  These  advantages  of  the 
U.S.  treatment process,  coupled  with the fact that higher German out- 
comes  per case resulted solely  from a higher surgical frequency,  led us 
to conclude  that the United States was more productive. 
Reasons for  the Differences 
Three differences  in provider behavior led to differences  in produc- 
tive  efficiency  between  the  United  States  and the  United  Kingdom: 
technology  adoption,  treatment duration, and staffing levels.  The pri- 
mary cause of the higher U. S. productive efficiency  was faster adoption 
of the laparoscopic  approach. Shorter hospital stays and postdischarge 
recuperation, which were at least partially related to the adoption of the 
laparoscopic  operation,  also increased U.S.  productive efficiency  rela- 
tive  to the United  Kingdom  and were  only  partially offset  by  higher 
levels  of hospital staffing. 
Differences  in staffing levels  and technology  adoption also affected 
productive  efficiency  differences  between  the United  States  and Ger- 
many, but differences  in treatment duration were especially  striking- 
German patients experienced  much longer hospitalizations  and conva- 
lescence  times  after discharge.  The slightly  later adoption of laparos- 
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added costs  of  higher levels  of  staffing  in the United  States,  the  net 
effect  of  these  other differences  led to lower  productive efficiency  in 
Germany. 
Breast Cancer 
Breast  cancer  is  a  leading  cause  of  cancer  mortality  in  all  three 
countries,  where  between  fifty-five  and ninety  cases  per  100,000 
women are diagnosed annually."0  This incidence translates to a lifetime 
risk of disease  on the order of  10 percent.  Female breast cancer rarely 
occurs before the age of thirty and is most often diagnosed at fifty years 
of  age  and older.  It is often  fatal because  it has a tendency  to spread 
from the breast to distant tissues  if left untreated. Currently, the only 
reliable cure for the disease  is to remove  it while  it is still localized  to 
the  breast,  an  option  that  frequently  is  not  possible  at the  time  of 
diagnosis.  There are no simple preventive steps that dramatically reduce 
individual risk. 
Management  and Treatment 
We divided the management and treatment of breast cancer into four 
phases:  screening;  assessment;  therapeutic;  and follow-up.  In the 
screening  phase,  patients with no prior indication of problems are ex- 
amined  for  the  presence  of  an abnormal tissue  mass.  The  resources 
consumed  by screening  and diagnostic  services  were substantial in re- 
lation to those consumed by treatment alone.  Furthermore, the patterns 
of screening and diagnosis  vary among the countries studied. If screen- 
ing indicates  that disease  may be present,  a woman enters the assess- 
ment  phase,  where  diagnostic  testing  and biopsies  are performed  to 
confirm or reject a malignant diagnosis.  The therapeutic phase, in which 
patients are treated for the cancer,  can include  interventions  designed 
to  remove  the  primary tumor and to  prevent  or halt  its  spread.  The 
follow-up  phase includes  all diagnostic  testing to monitor the patient's 
progress  after  treatment,  as  well  as  therapeutic  treatment upon  any 
relapse. 
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Inputs 
The input measure for breast cancer included all labor, capital,  and 
supplies  associated  with the procedures performed in the four phases. 
We did not include elective  reconstruction of the breast after a mastec- 
tomy.  A  preliminary analysis  revealed  that in the time  period of  our 
study,  few women underwent breast reconstruction in any of the coun- 
tries; the resources consumed by reconstruction were,  therefore,  likely 
to be small compared with the total cost of cancer care. In addition, the 
availability  of reconstruction likely  had little differential  effect  on the 
treatment approaches for cancer care in each country. 
Outcomes 
Our outcome  measure  is based  on  the percentage  of  women  diag- 
nosed with breast cancer who survive for five years following  diagnosis. 
This  measure is calculated  from survival  statistics  for relatively  large 
populations  of  breast  cancer  patients  in  each  of  the  three  countries 
during roughly  the  same  time  period.  From these  statistics,  we  con- 
structed age-adjusted,  five-year  survival curves and compared the sur- 
vival "profiles"  of each country. Before any adjustments, these profiles 
show  the highest  survival  rates in the United  States,  followed  by the 
United Kingdom  and then Germany. 
Ideally,  our outcome  measure  would  reflect  the  increment  to  life 
years  generated  by  breast cancer  treatment in each  of  the countries, 
relative  to the life  years  that would  have  occurred  in the absence  of 
treatment. This  could  not be done  systematically,  because  we  lacked 
information on the likely  five-year  survival rates of untreated individ- 
uals. Instead, we simply assumed that, left untreated, all patients would 
die right away.  This  procedure is very conservative  in that it reduces 
the percentage output advantage of the best outcome  country,  namely, 
the United  States.  Effectively  it means that the outcome  measures are 
not much different in the three countries. 
A  problem  with  using  five-year  survival  rates as  the  basis  of  the 
outcome  measure  is  that  screening  introduces  a  bias.  Suppose  two 
women contract breast cancer in the same year, say  1980.  The woman 
in Country A  is diagnosed  in  1980 by mammographic  screening;  the 
woman in Country B is diagnosed only in 1982,  after she finds a lump. 
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The  woman  in  Country  A  who  was  mammographically  screened  is 
shown as having survived five years after diagnosis,  but the woman in 
Country B  who  was  diagnosed  only  with  a lump  is  not.  In fact  the 
treatment did  not  affect  the  outcome.  A  bias  is  also  introduced  by 
women with slow-growing  tumors who would have lived out their nor- 
mal life spans even in the absence of treatment. Mammographic screen- 
ing discovers  and treats these  cases  and may count them as five-year 
successes  of  treatment when  in fact the treatment did not affect  their 
health outcome. 
Because the United States had mammographic screening in the 1980s 
(the time frame of our study),  while the United Kingdom had none and 
Germany had very  little,  we  adjusted the observed  five-year  survival 
rates in the United States. Once again, our procedure was conservative, 
because it sharply reduced the substantial unadjusted survival advantage 
of  the United  States  It was  assumed  that one-third  of  all  U.S.  cases 
were detected  by screening and that this introduced a lead-time bias of 
three years.2' 
Productive  Efficiency Differences 
Both the United  States and the United  Kingdom  were clearly  more 
productive  than Germany in treating breast cancer.  The United States 
used  38 percent fewer  inputs and achieved  9 percent better outcomes 
than Germany,  whereas  the  United  Kingdom  used  53  percent  fewer 
inputs and achieved  6 percent better outcomes.  The United States used 
15 percent more inputs and achieved  3 percent better outcomes than the 
United Kingdom,  which made it impossible  for us to determine which 
nation had higher productive efficiency.  This comparison is considered 
inconclusive  in terms of productive efficiency. 
In U.S.  prices,  the United  States  spent $32,000  more per life  year 
than the  United  Kingdom  for  treating  breast cancer;  that amount  is 
generally  considered  cost  effective.  In U.K.  prices,  the United States 
spent only  an additional  $13,000  per life  year,  which  suggests  that it 
21.  By using  five-year  survival  as the outcome  measure,  we  do not capture differ- 
ences  in the quality of life; data limitations prevented us from doing so.  In recent clinical 
trials,  researchers have been using  disease-free  survival  rates,  acknowledging  that sur- 
vival without the recurrence of cancer is potentially  more useful as an outcome  measure 
than raw survival.  Unfortunately,  disease-free  survival  rates were not widely  recorded 
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would clearly make economic  sense for the United Kingdom to increase 
the  resources  used  to  treat this  disease.  Keep  in  mind  also  that the 
procedures  for outcome  measurement  tended to reduce the measured 
U.S.  outcome  advantage. 
Reasons for  the Differences 
Once the adjustments were made to the measure, we found relatively 
small differences  in outcomes among the three countries.  Consequently 
in our analysis  of the reasons for the productivity differences,  we con- 
centrate on explaining  the differences  in inputs. 
Screening  practices had a significant effect  on differences  in overall 
input consumption  and productive efficiency.  At the time of our anal- 
ysis,  the United Kingdom had no formal screening program, and there- 
fore no resources  were considered  to be consumed  in this phase.22 In 
comparison,  the widespread adoption of screening  in the United States 
came  at a high  cost.  Screening  through mammography  and physical 
exam  accounted  for about  15 percent of the total resources  consumed 
in breast cancer care, with mammography accounting for most of these 
resources.  Much  of  this  activity  focused  on  premenopausal  women 
who,  in the absence  of risk factors,  were less  likely  to benefit from it 
than postmenopausal  women.  Physical  breast  exams  were  part of  a 
typical  gynecological  exam,  which  means  that women  as  young  as 
eighteen years underwent this type of screening.  Like the United States, 
Germany employed  both mammographic and physical exam screening. 
Overall,  Germany consumed  slightly  more resources  than the United 
States on screening but, on balance, consumed more on physical exams 
than on mammography. 
The broader the screened population (that is,  the younger the age at 
which screening began),  the more frequently screening resulted in false 
positive  cases,  leading to large additional  "downstream"  costs  in the 
assessment  phase.  That  is  because  younger  women  are much  more 
likely than postmenopausal women to have noncancerous abnormalities 
that are then detected and assessed.  This downstream cost was greatest 
22.  Forrest and others (1986);  clinician  interviews.  A small  number of women  are 
likely  to have  received  physical  exam  screens  in the United  Kingdom,  but there is no 
good estimate  for this level  of care. Therefore,  we did not include any screening  in our 
analysis of the total resource consumption  for breast cancer care in the United Kingdom. 168  Brookings  Papers: Microeconoinics 1997 
in  the  United  States  because  of  its  wide  use  of  mammography  on 
younger women,  which when compared with the mostly physical exam 
screening  in Germany,  identified  more nonpalpable  masses,  most  of 
which were benign.  By increasing costs  without producing substantial 
benefit, this broad-based mammographic screening lowered the United 
States's  productive efficiency  in breast cancer treatment.23 
The  protocols  in  the  assessment  phase  also  differed  in  the  three 
countries.  There can be either one-step  or two-step  procedures.  In the 
one-step procedure the patient undergoes a surgical biopsy in a hospital 
while  under general  anesthetic,  and  if  the  mass  is  cancerous,  it  is 
removed together with a mastectomy  or other treatment. In a two-step 
procedure,  a biopsy  is performed under local  anesthetic,  followed  by 
surgery at a later time if there is a finding of cancer.  A biopsy  can be 
performed  using  either  a surgical  biopsy  or a  fine needle  aspiration 
(FNA),  and it can be performed either on an inpatient or an outpatient 
basis. 
Over time,  there has been  a shift  away  from one-step  procedures. 
During  the  time  frame of  the  study,  the  United  States  had virtually 
completed  the shift to the two-step  procedure, but in Germany and the 
United Kingdom  80 percent of the procedures were still one step,  and 
these were all carried out in hospitals.  In the United States the first step 
was generally  a surgical biopsy  carried out in the doctor's  office.  The 
two-step  procedures used in the United Kingdom  involved  an FNA  in 
the first step, on an outpatient basis.  Biopsies  in Germany were carried 
out in the hospital even  in the two-step  cases. 
Because  outpatient biopsies  consume  fewer  resources  and because 
most patients who go on to the assessment  phase turn out not to have 
malignancies,  the United States was able to save substantial resources 
by performing  all  of  the biopsies  on  an outpatient basis  and using  a 
two-step  procedure.  This  advantage more than offset  the fact that the 
United States performed more biopsies  in total,  mostly  because  of  its 
screening  program.  Overall,  the  United  States  used  3  percent  fewer 
23.  In  1987  the  United  Kingdom  instituted  a  nationwide  breast cancer  screening 
program that did  not  become  fully  functional  until  1991.  Using  mammography,  the 
program is  restricted to women  over  the age  of  fifty  and currently calls  for screening 
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resources than the United Kingdom and 20 percent fewer resources than 
Germany on assessment.24 
In the therapeutic phase,  surgery is the most important treatment for 
breast cancer.  We observed differences  in the frequency of surgery, as 
well  as  in  the  mix  of  the  two  major types  of  surgeries  performed. 
Overall,  the frequency of surgery for the primary breast tumor was 91 
percent,  75 percent,  and 97 percent in the United States,  United King- 
dom,  and Germany, respectively.  Of those cases treated surgically,  the 
frequency of breast-conserving  surgery was 29 percent, 44 percent, and 
39  percent  for  the  United  States,  United  Kingdom,  and Germany, 
respectively.25 
Despite  the  differences  in  their frequency  of  surgery,  the  United 
States and United Kingdom consumed about the same level of resources 
for surgery and subsequent hospitalization;  Germany consumed  about 
50 percent more.  This is because  total resource consumption  depends 
not only on the frequency of surgery, but also on the lengths of hospital 
stay,  and these were shortest in the United States. 
Radiotherapy  and chemotherapy  were  often  part of  breast cancer 
therapy.  Chemotherapy  was  not a major part of  total resource  use  in 
any of  the countries  (3 to 4 percent).  Germany used 25 percent more 
resources  than the United  States  in chemotherapy  because  of  greater 
use of inpatient treatment. Radiotherapy was a somewhat more impor- 
tant component of total resource use (6 percent in the United States,  12 
percent in the United Kingdom,  and 5 percent in Germany).  And both 
the United Kingdom and Germany used greater total resources than the 
United  States  (60  percent and  10 percent more,  respectively).  There 
were a variety of offsetting  reasons for these findings.26 
0  The  United  Kingdom  gave  radiation  in  fewer  but  larger doses 
24.  Because  few  data were  available  on assessment  protocols,  the analysis  here is 
derived through interviews  with clinicians  in each of the three countries. 
25.  SEER database; Thames  Cancer Registry  database; Krebsregister-Saarland  da- 
tabase; Arbeitsgruppe  zur Koordination  Klinisher  Krebsregister database; Grosshadern 
dataset; Foreman and Rider (1995);  clinician  interviews.  The  frequency  rate does  not 
include surgeries performed upon recurrence of cancer. 
26.  Thames  Cancer Registry  database; Arbeitsgruppe  zur Koordination  Klinischer 
Krebsregister database; clinician  interviews. 170  Brookings  Papers:  Microeconomics  1997 
(saving  resources),  but used older equipment (requiring extra la- 
bor). 
*  The United  States  had higher staffing  levels  in hospitals,  which 
raised resource use for inpatient radiotherapy. The United  States 
performed less  radiotherapy,  largely  because  of  its less  frequent 
use of breast-conserving  surgery. 
*  The  United  Kingdom  did  more radiotherapy,  mostly  because  it 
did less  surgery than either the United States or Germany. 
*  The United States and Germany each consumed  about 30 percent 
of  total resources  in the therapeutic phase; the United  Kingdom 
about 39 percent.  The United  Kingdom  and Germany consumed 
3 percent and  11 percent more resources,  respectively,  than the 
United States.27 
Lung Cancer 
Lung cancer is the leading  cause  of cancer death in all three coun- 
tries.28 In 1995 lung cancer caused about 160,000  deaths in the United 
States  alone.29  The  disease  is  associated  with  cigarette  smoking  and 
develops  most often  in scarred or chronically  diseased  lungs.  Its poor 
prognosis  reflects  its advanced  state at the time it is usually  detected. 
Symptoms of lung cancer include persistent cough,  breathing difficulty, 
abnormal  sputum,  chest  pain,  and repeated  attacks  of  bronchitis  or 
pneumonia.  Lung cancers spread widely  to other organs; the extent of 
spread is a critical element  in determining  overall  prognosis  and type 
of treatment offered. 
Lung cancers are typically  grouped into two categories  according to 
cell  type.  Small  cell  lung cancer accounts  for 20 to 25 percent of the 
27.  Although  there are many options  relating to the procedures available  for moni- 
toring patients for relapse and for treating upon relapse,  the follow-up  phase itself  does 
not consume  many input resources relative to the other phases.  Because  the overall cost 
is small,  any practice differences  among the three health care systems  resulted in rela- 
tively  insignificant  resource  consumption  and productive  efficiency  differences.  Thus, 
the treatment differences  observed were less important in explaining input and productive 
efficiency  variations than differences  in the other phases. 
28.  World Health Organization  (annual). 
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cases  and has a particularly poor prognosis.3" Non-small  cell  lung can- 
cer accounts  for the balance of the cases  and can be cured if detected 
early.  Although  the  approaches  to  treatment  vary  between  the  two 
groupings  of  cancers,  in  general,  both  are managed  through one  or 
more  interventions-surgery,  radiotherapy,  chemotherapy,  and  sup- 
portive care. 
Because  lung  cancer  is  often  incurable,  therapy often  is  directed 
toward  more  limited  goals  than curing  the  disease.  Therapy can  be 
divided  into three classes:  curative; palliative  (amelioration  of  symp- 
toms only);  or supportive (maintaining  patient comfort without active 
therapy). 
The  intent of  treatment and specific  treatment options  are decided 
after discussion  between  physician  and patient. The extent of the can- 
cer,  its  cell  type,  and the patient's  physical  and emotional  condition 
determine which treatment is appropriate. 
Management  and Treatment 
We divided  the management and treatment of lung cancer into three 
distinct phases: diagnosis  and staging; curative care; and palliative care. 
The purpose of the diagnosis  and staging phase is to identify  the con- 
dition as lung cancer,  assess the cell type of the disease,  and determine 
the size  of the primary tumor and the extent of  spread to distant parts 
of the body.  The information gained in this phase is used to assess  the 
appropriate course  of  treatment-whether  curative  care  or palliative 
care. These two treatment options represent the second and third phases 
in the management of lung cancer.  Curative care,  warranted in only  a 
minority  of  cases,  is  aggressive  and attempts to eradicate the cancer 
and return the patient to full health. Palliative care offers an alternative 
when a patient has little chance of cure or when curative care has failed 
to eradicate the disease.  Palliative  care takes two different forms: an- 
ticancer palliative  care (which includes any noncurative intent surgery, 
chemotherapy,  or radiotherapy directed at a tumor site) and supportive 
care (which  includes  any other palliative  care). 
30.  Metastases  are tumors that form in parts of  the body  remote from the primary 
tumor and are the product of cancer spreading from the primary site. 172  Brookings  Papers: Microeconomics 1997 
Inputs 
The input measure covers  all the labor,  capital,  and supplies  asso- 
ciated  with  the procedures  performed in the three phases  of  manage- 
ment. We excluded  "best  supportive care"  in the palliative care phase 
because no reliable data could be found to cover it. We believe  that the 
resource consumption  involved  was  small and that differences  among 
countries were likely  insignificant. 
Outcomes 
The median survival of lung cancer patients is about a year, and only 
about 10 percent of cases survive five years after diagnosis.  A five-year 
survivor has a high likelihood  of being cured of the disease,  and so, for 
the basis of our comparison,  we chose an outcome measure of life years 
saved based on the cumulative  five-year survival curve. 
Most outcome measures for lung cancer, like those for breast cancer, 
are problematic.  Analysis  based  solely  on survival  duration does  not 
adequately  take into account the quality of life.  Undoubtedly,  an out- 
come  measure adjusted for quality of  life  would  handle this potential 
problem,  but we were unable to use such a metric because the required 
data were unavailable.  We believe,  however,  it is reasonable to assume 
that no significant  differences  in treatment preferences  existed  among 
countries  and that therefore  our use  of  five-year  survival  provides  a 
reasonable  basis for outcome  comparison.3 
Productive  Efficiency Differences 
Germany used 21 percent more inputs and achieved  12 percent worse 
outcomes  than the United States in the treatment of lung cancer.  With 
better outcomes  and fewer  inputs,  the United  States was clearly  more 
productive than Germany in lung cancer treatment. 
3 1.  The availability  of treatment options  for terminal patients may affect  the shape 
of the five-year  survival curve but should not affect the percentage of cases that actually 
survive.  This difference  in curve shape occurs because in a resource-constrained  system, 
terminal patients are less  likely  to gain access  to treatments such as chemotherapy  and 
thus may die  sooner,  which  changes  the shape of the survival curve.  These  conditions 
may  have  been  present  in  the  United  Kingdom,  so  a  small  portion  of  the  outcome 
difference  between  the United Kingdom  and the other two countries may be due to the 
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The United Kingdom used 24 percent fewer inputs and achieved  58 
percent lower outcomes  than the United States in the treatment of lung 
cancer. In this case, measuring average productivity requires comparing 
each nation's  outcomes  with treatment to outcomes  without treatment. 
Average  productivity  was  thus  calculated  using  five-year  survival 
curves to determine each nation's outcome with treatment and a baseline 
estimate  of  3.8  months  survival  without  treatment.  That  measure 
showed  that average productivity  was 82 percent higher in the United 
States  than in  the  United  Kingdom.32 Because  the disease  treatment 
process  did not appear to exhibit  increasing  returns at the positions  of 
the United Kingdom and the United States, we conclude that the United 
States  was  more productive  than the United  Kingdom  in lung  cancer 
treatment. 
The United Kingdom used 37 percent fewer inputs and achieved  52 
percent lower outcomes  than Germany.33 Based on five-year  survival, 
Germany had 33  percent higher average productivity  than the United 
Kingdom,  and so  we  concluded  that Germany  was  more productive 
than the United Kingdom in lung cancer treatment. 
Reasons for  the Differences 
The United  States  demonstrated greater productive  efficiency  than 
the United  Kingdom  for two  main reasons:  shorter hospital  stays  for 
surgery; and substitution of outpatient for inpatient chemotherapy.  The 
United  States  also  used  CT  (computerized  tomography)  scans  more 
frequently in diagnosis  and staging than the United Kingdom did; these 
scans made it possible to target treatment toward the patients who would 
benefit most and ultimately improved outcomes.  Although higher staff- 
ing levels  diminished  the United States's  productive efficiency  relative 
to that of the United Kingdom,  the net result of differences  in treatment 
was higher productive efficiency  in the United States. 
32.  SEER database; Joslin  and Rider (1993).  In our data search,  we  found  no ex- 
amples of a clinical  trial that compared outcomes  for treated versus untreated cases.  We 
did,  however,  find survival  curves  for untreated cases  (that is,  patients who  received 
only  basic  support care; these results are the basis for our estimate  of 3.8  months.  The 
cases  that underlie  these  untreated curves  obviously  do  not reflect  an adequate  cross 
section of all lung cancer cases.  Thus,  survival curves and our estimate likely understate 
the  true average  survival  for  untreated cases.  We  believe  that this  understatemlent is 
small and contributes insignificantly  to our outcome  calculation. 
33.  Calculation  based on ratio of German results to those  in the United Kingdom. 174  Brookings  Papers: Microeconomics 1997 
Germany's  productive  efficiency  relative  to the United  States  was 
lowered by its longer hospital stays and its greater use of the inpatient 
setting for chemotherapy.  Although its lower staffing levels  raised Ger- 
many's productive efficiency  relative to the United States, the net effect 
of provider treatment differences  led to higher productive efficiency  in 
the United States. 
Differences  in  the  frequency  and type  of  diagnostic  testing  had a 
significant  effect  on differences  in overall  input consumption  and pro- 
ductive  efficiency.34  In general the United  Kingdom  performed fewer 
diagnostic  tests  per lung cancer patient than did the United  States  or 
Germany. The most important differences  in behavior were in the areas 
of CT scans, endoscopic  exams,  and biopsy,  where the United Kingdom 
appears to underinvest relative to the United States and Germany. Only 
about 20 percent of cases  in the United Kingdom were assessed  with a 
CT scan,  compared with 80 percent in the United  States and close  to 
100 percent in Germany. 
In the United  States the diagnosis  and staging  phase accounted  for 
about 21 percent of all resources devoted to lung cancer, compared with 
about 18 percent in the other two countries.  The United Kingdom con- 
sumed 8 percent fewer resources than the United States; Germany con- 
sumed  1 percent  more.  The  resources  consumed  during the curative 
care management phase, on average,  accounted for about 40 percent of 
total resources  devoted  to lung cancer care.  Surgery was responsible 
for  more  than half  of  these  resources.  Radiotherapy  played  a  lesser 
though  important role,  accounting  for  about 20  percent  of  these  re- 
sources.  Chemotherapy,  which was used infrequently,  rounded out the 
care, consuming about 10 percent of the resources devoted to this phase. 
The total resources committed to surgery differed significantly across 
the three countries.  Resource consumption was driven by the frequency 
of surgery, the length of hospital stay during recovery,  and the level  of 
hospital staffing. The surgical frequency was highest in Germany, with 
about 30 percent of all lung cancer patients receiving surgical treatment. 
The United  States  and the United  Kingdom  followed  with 22  percent 
and 13 percent, respectively.  Shorter lengths of stay in the United States 
were partially offset by higher hospital staffing levels.  Accounting  both 
34.  Edinburgh Lung Cancer Group (1987);  Humphrey and others (1990);  Scotland 
data, unpublished; clinician  interviews.  The frequencies  of CT scanning,  bronchoscopy, 
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for differences  in frequency of surgery and in resources per operation, 
we  concluded  that the  United  Kingdom  consumed  25  percent  fewer 
resources than the United States,  and Germany 60 percent more. 
The drivers of differences  in resource consumption  associated  with 
radiotherapy were similar to those driving differences  in surgery. Most 
radiotherapy was performed in the outpatient setting,  however,  which 
meant that the length of hospital  stay and staffing factors were of less 
importance than for surgery. 
Chemotherapy was a relatively  minor part of the curative care man- 
agement phase in that its frequency was quite low in all three countries. 
The setting of chemotherapy care differed considerably,  however,  with 
the United  Kingdom  and Germany using  an inpatient setting far more 
than did the United  States.  As a result,  overall  resource consumption 
for the United  Kingdom  and Germany was about  120 percent and 90 
percent greater, respectively,  than that in the United States. The pallia- 
tive care management phase,  on average,  accounted for about 40 per- 
cent of total resources devoted to lung cancer care. In general,  patterns 
of  palliative  care  paralleled  patterns of  curative  intent  care  in  each 
country. 
Summary  of the  Case  Findings 
Figures  5  and 6  summarize  the  outcomes  and inputs for  the  four 
diseases,  which are indexed so that the U.S.  outcomes  and inputs equal 
100.  In  all  of  the  diseases,  the  United  Kingdom  used  the  smallest 
amount of inputs,  the United States used more,  and Germany used the 
most.  The  United  States  had the most  favorable  outcomes  for breast 
and lung  cancer; the United  Kingdom  for diabetes,  and Germany for 
cholelithiasis.  Table  1 summarizes  the resulting productive efficiency 
findings. The United States appears to have the highest productivity for 
lung  cancer  and cholelithiasis;  the  United  Kingdom  has  the  highest 
productivity  for diabetes.  For breast cancer the outcome  is indetermi- 
nate between  the  United  States  and the United  Kingdom,  which  has 
lower  outcomes  but also  lower  inputs.  It does  appear, however,  that 
the United Kingdom devoted  too few resources to this disease. 
Table 2 summarizes the differences  in provider behavior that account 
for the input and outcomes  differences.  We have divided these behav- 176  Brookings  Papers:  Microeconomics  1997 
Figure 5. Inputs by Disease 
U.S. = 100 
CHOLELITHIASIS 
U.K.  44 
U.S.  100 
Germany  172 
BREAST  CANCER 
U.K.  85 
U.S.  100 
Germany  138 
LUNG  CANCER 
U.K.  76 
U.S.  ;100 
Germany  X^  i  121 
DIABETESa 
U.K.  66 
U.S.  100 
Germany  Not studied 
Source:  McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
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Figure 6. Outcomes  by Disease:  Improvement  in Outcomes  Because  of Treatment 
U.S. = 100 
CHOLELITHIASISa 
Quality-adjusted life years (QALYs)  QALYs 
U.K.  _  24  0.05 
U .  S.  >>s>>  x  g  |l  1  00  0.2 1 
Germany  110  0.23 
LUNG  CANCERb 
Life years (LYs)  LYs 
U.K.  _  42  0.22 
U.S.  100  0.52 
Germany  88  0.46 
BREAST CANCERC 
Life years (LYs)  LYs 
U.K.  97  3.73 
U.S.  100  3.87 
Germany  9 1  3.51 
DIABETESd 
Quality-adjusted life years (QALYs)  QALYs 
U.K.  127  6.41 
U.S.  3100  5.05 
Germany  Not studied 
Source:  McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
Note: Improvenment  is relative  to baseline outcome with no treatment. 
a. Outcomes  based on thirty-day  frequency  of symptoms. 
b. Outcomes  based on five-year  survival. 
c. Outcomes  based on five-year  survival;  baseline outcome with no treatment  assumed  to be immediate  death. 
d. Weighted  average of Type I and Type II; baseline outcome with no treatment  assumed  Type I diabetics  die within a year and 
Type II diabetics  have same QALYs  as lowest outcomes with treatment  (U.S.). Table 
1. 
Relative 
Productive 
Efficiency 
by 
Disease 
Case 
U.S. 
vs. 
U.K 
U.S. 
vs. 
Germany 
Germany 
vs. 
U.K. 
More 
More 
More 
productive 
productive 
productive 
Disease 
Inputs 
Outcomes 
country 
Inputs 
Outcomes 
country 
Inputs 
Outcomes 
country 
Cholelithiasis 
4 
4 
U.S. 
* 
U.S. 
4 
+ 
Germany 
Lung 
cancer 
4 
4 
U.S. 
* 
+ 
U.S. 
4 
+ 
Germany 
Breast 
cancer 
+ 
4 
Indeter- 
* 
+ 
U.S. 
+ 
U.K. 
minate 
Diabetes 
+ 
U.K. 
Not 
studied 
Not 
studied 
Source: 
McKinsey 
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and 
the 
McKinsey 
Health 
Care 
Practice 
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Table  2.  Specific  Differences  in Provider  Behavior  Identified  in Case Studies 
Provider  U. S. vs.  U. K. 
behavior 
difference  Diabetes  Cholelithiasis  Breast cancer  Lung cancer 
Care  Clear triaging of  Much less  No screening in  More use of 
triaging  diabetics for  frequent surgery  U.K.;  more  "supportive 
care  in U.K.  lumpectomy  care only"  in 
management  and  U.K.;  less 
resources in  radiotherapy in  radiotherapy in 
U. K.  U.K.;  more  U.K.;  more 
chemotherapy  diagnostic 
in U.S.  testing in U.S. 
and less surgery 
in U.K.  given 
complex and 
lengthy referral 
process 
Length of  Longer stay for  Longer stay,  Longer surgical  Longer surgical 
hospital  complications  longer patient  stay in U.K.  stay in U.K.; 
stay  treatment in  recovery time in  shorter 
U.K.  U.K.  radiotherapy 
stay in U.K. 
Staffing  Lower hospital  Lower hospital  Lower hospital  Lower hospital 
levels  staffing in U.K.  staffing in U.K.  staffing in U.K.  staffing in U.K. 
Setting  .  .  .  .  .  .  More inpatient  More inpatient 
choice  biopsy in U.K.;  chemotherapy 
maintenance of  in U.K.;  more 
one-step biopsy-  outpatiet 
surgical  chemotherpy in 
treatment  U.S. 
protocol 
Team-based  Multispecialty  .  .  .  .  .  .  ... 
approach  diabetic clinics 
in U.K. 
Technology  .  .  .  Later  Use of fine  Less use of 
adoption  laparoscopic  needle  computerized 
adoption in  aspiration in  tomography 
U.K.  U.K.  vs.  scan for staging 
surgical biopsy;  in U.K. 
no 
mammographic 
screening in 
U.K. 
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Table 2.  (continued) 
Provider  U.S.  vs. Germ71anv 
behavior 
difference  Cholelithiasis  Breast cancer  Lung cancer 
Care  Slightly more  Broader  More frequent 
triaging  frequent surgery  screening and  surgery in 
in Germany  more  Germany 
lumpectomy in 
Germany 
Length of  Longer 
stay, 
Longer surgical  Longer surgical 
hospital  longer patient  stay in Germany  stay in Germany 
stay  recovery time in 
Germany 
Staffing  Lower hospital  Lower hospital  Lower hospital 
levels  staffing in  staffing in  staffing in 
Germany  Germany  Germany 
Setting  .  .  .  Inpatient biopsy  More inpatient 
choice  in Germany vs.  chemotherapy 
outpatient in  in Germany 
U.S.;  more 
inpatient 
chemotherapy 
in Germany 
Team-based  .  .  .  .  .  .  . 
approach 
Technology  Slightly later  More  . 
adoption  laparoscopic  mammographic 
adoption in  screening in 
Germany  U.S. 
Source: M'Kinsey Global Inistitute  and the McKinsey Health Care Praictice  ( 1996). Martin  Neil Baily and Alan M. Garber  181 
ioral  differences  into  six  categories.  Care  triaging  reflects  the  ap- 
proaches to screening and to the allocation  of resources once diagnosis 
has been made. The United Kingdom is notable for doing less screening 
and less  surgery  for  the  cancers  and less  surgery  for  cholelithiasis. 
Patients with cholelithiasis  and lung cancer in the United Kingdom are 
more likely  to be assigned  to palliative  care than in the United  States 
The  situation  is  different  for  diabetes,  where  triaging  in the  United 
Kingdom  contributed to both lower  inputs and higher outcomes.  The 
United  Kingdom  and particularly Germany had longer  hospital  stays 
than did the United States. The United States had higher staffing levels 
per hospital  day  than the  other two  countries;  these  staffing  levels, 
however,  only partially offset  the input advantage to the United States 
of the short lengths  of stay. 
Choice  of  setting  was  also  a  factor,  with  treatment taking  place 
outside  hospitals  in the United  States  more often  than in the United 
Kingdom and much more often than in Germany. In our cases,  the team 
approach  was used only by the United Kingdom and only for diabetes. 
Nonetheless,  we judge  this  approach to  be  an important example  of 
treating a chronic disease,  using a specialized  clinic and fewer resources 
to achieve  better outcomes.  Finally,  technology  adoption  was  impor- 
tant.  For lung  cancer  (CT scans)  and for cholelithiasis  (laparoscopic 
surgery), the more rapid adoption of technology  improved U.S.  perfor- 
mance.  Technology  adoption was  notably slower  in the United  King- 
dom and somewhat  slower  in Germany.  Conversely,  the rapid spread 
of mammographic screening technology,  applied to patients where the 
effect  on outcomes  is minimal,  hurt U.S.  performance. 
Differences in Provider Incentives, Constraints, and 
Regulations 
These  differences  in treatment protocols  gave  rise to different pro- 
ductive  efficiencies.  But what causes  differences  in the approaches to 
treatment? Differences  in medical knowledge  are unlikely to be respon- 
sible.  The medical literature is available to all, and methods of training 
doctors are fairly similar. The differences  in the incentives  that provid- 
ers faced in the three countries were striking,  however,  and those dif- 
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and differences  in other aspects of medical practice. We concluded that 
the variations  in incentives-as  well  as differences  in regulatory and 
other constraints-explained  much of the difference  in productive  ef- 
ficiency  that we observed. 
Major Differences  between the United States and 
the United Kingdom 
Most  physician  services  in the United  States,  including  both  spe- 
cialist  and primary care,  were  negotiated  and compensated  on a fee- 
for-service  basis  by  payors.  Physicians  aggressively  competed  for 
patients, and to a lesser extent, for payor contracts. The U.S.  physicians 
also faced the threat of malpractice suits. 
Although U.S.  payors faced some price-based competition and could 
have bundled and negotiated  services  in a variety of ways,  they were 
not an effective  force to counterbalance incentives to increase physician 
activity and technology  during the time period we were studying.  With 
indemnity coverage,  locally  prevailing  practices determined physician 
payments.  The U.S.  physicians  as a group were able to use local med- 
ical  associations  and specialty  societies  to promote  changes  in these 
practices,  leading  to increases  in standards of  care and thus to health 
insurance coverage  for higher activity  levels  or new technology  adop- 
tion.  U.S.  payors  were  often  forced  to  adopt such  coverage  in their 
health insurance products to meet employer and consumer demands for 
new treatment approaches and thereby to compete effectively;  the tax- 
preferred  treatment  of  health  insurance  premiums  magnified  this 
pressure. 
In contrast, specialist  physician services in the United Kingdom were 
negotiated  in  the  form  of  an  annual  salary  for  a  range  of  services 
performed by the National  Health Service  (NHS)  through its regional 
health  authorities; however,  specialists  could  also  earn additional  in- 
come  by  treating  private patients.  Thus  the  U.K.  specialists  had no 
economic  incentives  to increase  the amount of  care provided to NHS 
patients.  Indeed, to the extent that they had alternative income sources 
(from private practice, for example),  they may even have had an incen- 
tive  to limit the time  devoted  to NHS  patients.  In addition,  the U.K. 
specialists  had few  incentives  to  adopt new  technologies,  unless  the 
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General practitioner  services  in the United Kingdom took the form 
primarily of fee-for-service  contracts, with rates negotiated on the basis 
of  a complex  formula  through the  NHS.  In principle,  therefore,  the 
general practitioners had an incentive  to increase  treatment intensity. 
In practice,  however,  this was not the case because the NHS controlled 
both the supply of doctors and the fee payments.  Given the tight phy- 
sician  supply  and the structure of  the NHS  contracts,  neither the UK 
specialists  nor general practitioners competed  in any meaningful  way 
for NHS patients. 
As  the  organizing  force  for health  care  in the  country  and as the 
employer  of  many of  the physicians,  the NHS  was  able to  influence 
physicians  through training,  dissemination  of  information  and guide- 
lines,  and, if necessary,  through direct authority. The NHS,  therefore, 
contributed to physicians'  greater concern for cost effectiveness  in the 
United Kingdom and thereby to their greater willingness  to adopt tech- 
nology  more  slowly  and selectively.  By  internalizing  the  interaction 
between  payors  and physicians,  the United  Kingdom  may have been 
better able to apply these controls than the U.S.  payors were able to do 
through  arm's-length,  competitive  interactions  with  physicians.  The 
U.S.  payors lacked market power relative to physicians,  primarily be- 
cause  the payors'  customers-employers-did  not aggressively  resist 
cost  increases  until the early  1990s. 
A consistent  finding of international productivity comparisons is that 
competition  promotes high productivity.  Competitive  intensity in both 
care  provision  and health  coverage  was  much  greater in the  United 
States, which helps explain its relatively  high productivity for lung and 
breast cancer and cholelithiasis  compared with that in the United King- 
dom.  The  health  care  market  is  subject  to  several  types  of  market 
failure,  however,  that can distort the effect  of competition.  Third party 
payment encourages excessive  treatment (the moral hazard problem),  a 
problem that can be exacerbated by the tax treatment of health insurance 
premiums.  We did find that the United States provided more treatment 
than  the  United  Kingdom,  consistent  with  this  activity-increasing 
incentive. 
The methodology  used in these international comparisons  is not de- 
signed to determine the optimal level  of expenditures.  We restrict our 
analysis  to the empirical  comparisons  of resources used and the asso- 
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levels  of treatment in the United States generally led to better outcomes 
relative to the United Kingdom.  In particular, the improvement in out- 
comes  for lung cancer,  breast cancer treatment (as opposed  to screen- 
ing),  and cholelithiasis  in the United States were large when compared 
with the increments  in inputs.  Moreover,  one alleged  symptom of ex- 
cessive  treatment is the use of new technology  that is not cost effective. 
We  found,  however,  that in the  case  of  cholecystectomy,  the  rapid 
adoption  of  new  technology  improved  productivity  relative  to  the 
United Kingdom. 
An important qualification  to this conclusion  occurred when third- 
party payment was combined  with incomplete  information.  For exam- 
ple,  providers  offered  mammographic  screening  to  premenopausal 
women because patients demanded it and insurers paid. We found little 
or no  improvement  in outcomes  in the United  States  associated  with 
such  screening  despite  the  substantial  costs  involved.35  Many  of  the 
costs  resulted from false positives  from the screening. 
Adverse  selection  is a form of market failure that could not occur in 
a universal  health care system  but that has major consequences  in the 
United  States.  U.S.  payors  have  an incentive  to  avoid  patients  with 
chronic  or expensive  diseases,  whose  expected  health care costs  are 
higher than their premiums.  Specifically,  payors have an incentive  to 
avoid  diabetic  patients  because  they  generate  above-average  claims. 
Adverse  selection  has thus made it less  attractive for U.S.  providers to 
establish diabetes clinics  of the type developed  in the United Kingdom. 
Diabetes  clinics  have  been  established  in the United  States,  but they 
have had trouble obtaining  patients  with  insurance coverage.  The re- 
payment  schedules  established  by private payors for doctor visits  for 
diabetic patients exacerbated the difficulties  of treating this disease  in 
the United  States.  And the schedules  for the private sector were rein- 
forced by similar schedules  for Medicare and Medicaid,  which did not 
cover  the cost  of  a diabetologist.  Historically,  many diabetic  patients 
in the United States have been treated by general practitioners who did 
not carry out routine  foot  exams-an  essential  step  in avoiding  foot 
ulcers and possible  amputation. 
The success  of the United  Kingdom's  approach to diabetes  did not 
35.  Screening  of  postmenopausal  women  is  likely  to  be  more cost  effective.  The 
United Kingdom has now  instituted such a mammographic  screening  program. Martin  Neil Bailv anid  Alan M. Garber  185 
come from offering more treatment to all, but in large part from training 
patients in methods of self-care.  Such an approach made sense for the 
NHS,  which  had lifetime  responsibility  for patients.  The U.S.  payors 
generally  provided health coverage  for one-year terms and faced rela- 
tively  high annual turnover in their member populations  (20 to 40 per- 
cent).  This reduced their incentive  to make investments  in preventive 
or education-oriented  care that had a longer-term payback. 
Differences  in physician  and hospital  supply  were  also  important. 
The United Kingdom exercised  strict controls over the number of phy- 
sicians  and  the  number  and capacity  of  hospitals  through the  NHS 
budgeting  process  and regulations.  In the United  States the supply of 
physicians  and hospitals  was relatively  unconstrained,  although licen- 
sing requirements serve as an entry barrier. Supply constraints contrib- 
uted to the differences  in the amount and intensity of care provided in 
the two  countries.  Physician  and hospital  capacity  constraints  in the 
United  Kingdom  forced  providers  to  be  more  selective  in  choosing 
patients to treat and to substitute procedures that conserved  scarce re- 
sources.  Thus,  for  example,  they  adopted  fine  needle  aspiration  for 
breast cancer biopsy,  which  requires neither a hospital  admission  nor 
the services  of a surgeon. The selection  process could either be explicit 
(for example,  through providers'  decisions  to limit care or resources) 
or implicit  (through patient queuing,  for example). 
The NHS  budgets also explicitly  limited funding for capital invest- 
ments. Most funds were controlled at the regional or district level rather 
than incorporated into local hospital annual budgets. In these allocation 
decisions,  the NHS considered the cost-effectiveness  of a new technol- 
ogy  in  treating  a  specific  disease,  as  well  as  the  effect  of  a  given 
technology  on the overall system; for example,  the regional and district 
health authorities could consider the effects  of increased availability  of 
CT scans  for lung cancer diagnosis  and staging  on systemwide  usage 
and costs.  These funding limits and allocation processes  contributed to 
the slower  adoption and narrower use of capital-intensive  technology, 
such as mammographic equipment,  CT scans,  and laparoscopic equip- 
ment, in the United Kingdom relative to the United States. In addition, 
funding  limits  may  have  precluded  substitution  of  more  capital- 
intensive  resources,  such as CT scans,  for other care resources. 
In the United States individual hospitals and physicians  decided how 
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demand for new  technology  on the part of  both patients  and payors, 
with reasonable confidence that payors would reimburse patients treated 
with these technologies. 
Major Differences  between the United States and Germany 
German hospitals  had strong incentives  to increase their lengths  of 
stay; the U.S.  hospitals had incentives  to reduce them. These incentive 
differences  led to significantly  lower productive efficiency  in Germany, 
observed  in all three case study comparisons. 
German hospital  services,  including  physician  services,  were,  by 
law,  negotiated  and compensated  on a per diem basis with the payors. 
In contrast, the U.S.  hospital services were negotiated and compensated 
on a case rate basis from Medicare (through the diagnosis-related  group, 
or DRG,  system)  and through a mixture of  approaches  from private 
insurers that included fee-for-service,  per diem charges, and case rates. 
Case rates accounted for 35 to 40 percent of an average U.S.  hospital's 
total revenues. 
The incentives  U.S.  hospitals faced depended on whether they were 
being reimbursed on a case-rate or per diem basis; they could,  in prin- 
ciple,  have used different lengths of stay for the two classes  of patient. 
In practice  it  is  difficult  for  doctors  to  apply  different  protocols  to 
patients in adjacent hospital beds.  Thus the incentives created by case- 
rate reimbursement influenced the treatment protocol for everyone. 
The  use  of  per  diem  rates  gave  German  hospitals  an  immediate 
incentive  to extend  lengths  of  stay.  This  incentive  was reinforced  by 
the fact that German hospitals faced the threat of regulatory review and 
capacity  cuts if their utilization  fell  below  85 percent.  By maintaining 
high occupancy,  hospitals  avoided this threat. 
Specialist  physicians  in Germany were employed  by their hospitals 
and paid a flat salary; thus these physicians appeared not to have a direct 
economic  incentive  to increase the amount of care provided.  They had 
clear  "noneconomic"  incentives  to further the interests  of  their em- 
ployers,  the hospitals,  however,  and therefore had a relatively  strong 
incentive  to increase the amount of  inpatient care they provided.  Be- 
sides incentives  to maintain high enrollment,  there was an incentive  to 
select inpatient rather than outpatient care and to prolong hospital stays. 
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for  increasing  the  workload  of  their hospitals;  each  department was 
allowed  bed capacity  for private patients in a relatively  fixed ratio to 
its utilized  public beds,  so that the workload of the hospital from pub- 
licly funded patients had an indirect but significant effect on the chief's 
private income. 
CONSTRAINTS  ON  HOSPITAL  CAPACITY  IN  GERMANY.  Hospital capacity 
in Germany was seemingly  constrained,  whereas the U.S.  capacity was 
relatively unconstrained; yet Germany had more hospital beds per capita 
than the United  States.  The German constraint, therefore,  had the per- 
verse  effect  of  increasing  supply  and (in combination  with the above 
incentives)  encouraging longer and more frequent use of inpatient treat- 
ments. 
Capacity was regulated by state governments,  which had an incentive 
to maintain or increase the number of hospital beds because they created 
jobs  and resulted in transfers from federal payor funds into state econ- 
omies.  In addition, regulations required that payors partially fund losses 
at hospitals;  thus,  unlike  hospitals  in the United  States,  hospitals  in 
Germany did not face  the threat of  closure  if they  were  not covering 
costs.  Furthermore, the regulations and system structure that increased 
hospital  capacity  in Germany also  increased  the number of  hospital- 
based physicians. 
REGULATION  OF  INPATIENT  AND  OUTPATIENT  SEGMENTS.  These  seg- 
ments of care in Germany were strictly separated, governed by different 
organizations  and regulatory authorities,  and the type of care that each 
could provide was specified by law. This constraint created a barrier to 
substitution and coordination between the two sides and specified many 
services  to be performed in the inpatient setting,  leading to greater use 
of inpatient services.  In particular, because  of regulation,  substitution 
of less resource-intensive  outpatient procedures for inpatient procedures 
did not occur in Germany to the extent it did in the United States, where 
providers were relatively  free to use whatever care settings they chose. 
For example,  the U.S.  providers typically  used an outpatient surgical 
biopsy  for breast cancer  assessment,  whereas  German providers used 
an inpatient surgical  biopsy;  similarly,  the United  States replaced  in- 
patient chemotherapy with outpatient chemotherapy more quickly than 
Germany did. 
Overall,  the constraints on hospital  supply and substitution in Ger- 
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its greater use of inpatient services  as well as longer treatment lengths, 
lowering  its productive efficiency  relative to the United States. 
Reconciling Aggregate and Disease Case Level Performance 
We noted at the beginning of this paper that the performance of each 
country's  health care system  has been assessed  by comparing life  ex- 
pectancy (as the measure of outcomes)  to the level of health care spend- 
ing  (the  measure  of  inputs).  Our disease-level  analysis  has  assessed 
relative  productive  efficiency  in terms of  (quality-adjusted)  life  years 
per quantity of  input usage  at the disease  case  level.  And the results 
from the case  studies  seem quite different from the aggregate picture. 
The  diseases  we  studied  are  common,  important,  and,  we  believe, 
representative,  so the discrepancies  in findings are surprising.  Several 
factors may explain  the discrepancy  with aggregate data. 
On the outcomes  side, the disease-level  analysis generally concluded 
that U.S.  outcomes  compared favorably  with those  in the other coun- 
tries, while the aggregate data on life expectancy  slightly  favored Ger- 
many and the United Kingdom.  On the input side,  aggregate spending 
per capita is  much lower  in Germany than in the United  States,  even 
though the United  States used fewer  resources  per case.  The discrep- 
ancy between  the aggregate and disease-level  results is not as wide for 
the United Kingdom,  given that both our results and the aggregate data 
show low  input levels. 
There are four main explanations  for the differences  in results be- 
tween the aggregate and the case study analysis.  First, the incidence  of 
diabetes,  breast cancer,  and lung cancer might be higher in the United 
States than in the other countries.  Second,  the factors of  production, 
notably doctors'  salaries,  are priced much higher in the United  States. 
Third,  the  United  States  carries  a  substantial  administrative  burden 
relative to the other countries.  Administrative  costs  were not included 
in our disease  analyses.  Fourth,  life  expectancy  is heavily  influenced 
by neonatal mortality,  which  is higher in the United States than in the 
other two countries.  Although impaired access  to health services  and a 
lack of productivity in this medical activity could contribute to the less 
favorable  birth outcomes  in the  United  States,  neonatal  mortality  is 
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ual health behaviors,  that are not strongly related to health care deliv- 
ery.  Overall life  expectancy  at birth, then,  may be an unsuitable mea- 
sure of  health outcomes  for the purpose of  measuring productivity  of 
health services. 
Inputs at the Aggregate  and Disease  Case Levels 
Although data limitations precluded direct study of input usage on a 
national level,  proxies for the most important components exist.36 Com- 
parison of various medical inputs used per capita, including physicians, 
hospital medical  personnel,  hospital bed-days,  and drug prescriptions, 
showed  a pattern across  the three countries  similar to our findings  at 
the disease  case level  (figure 7).37 Germany used more of each of these 
inputs per capita than the United States,  which in turn used more than 
the United Kingdom (except for prescription drugs). Thus the aggregate 
data are directionally consistent with the disease-level findings. The rela- 
tive magnitude of the input differences at the aggregate and disease case 
levels is also very similar in the U.S.-U.K.  comparison (figure 8). 
Our case  results,  however,  show  considerably  higher  input use  in 
Germany than the level  suggested  by aggregate data. Among  the pos- 
sible  explanations  for this discrepancy  are higher disease  incidence  in 
the United States, the inpatient focus of the sample of diseases  studied, 
and data limitations. 
HIGHER DISEASE  INCIDENCE IN  THE  UNITED  STATES.  Use of medical 
inputs per capita is driven by both disease-level  productive efficiency 
(inputs per case)  and the incidence  and mix of diseases  in each country 
(cases  per capita).  Incidence  rates for breast and lung cancer are 27 to 
36 percent lower in Germany than in the United States. Thus, the higher 
input usage per case in Germany is slightly offset by the greater number 
of cases  of lung and breast cancer in the United  States.  The incidence 
of diabetes  in the United Kingdom is less  than half the U.S.  rate. The 
two  cancers  have greater input usage  per case  than diabetes  and cho- 
lelithiasis,  so  their  weight  in  the  total  is  magnified.  Thus,  different 
incidence  rates can explain  part of the inconsistency  in magnitude be- 
tween  aggregate and disease-level  input usage. 
36.  Data  on  hospital  supplies  and capital  usage  were  not  available  on  a national 
basis. 
37.  The category  called  hospital personnel  includes  medical  technicians  and nurses 
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Figure  7. Medical  Inputs by Country,  1990 
U.S. = 100 
AVERAGE  INPUTS  PER  ACTIVE  PHYSICIANS 
DISEASE  CASE  PER  1,000  POPULATION 
Germany  144  135 
U.S.  101  0  0  00 
UK  67  61 
HOSPITAL  STAFFa  DRUG  PRESCRIPTIONS 
PER  1 ,000  POPULATION  PER CAPITA 
Germany  118  120b 
U.S.  100  m  100 
U.K.  60  105 
Source:  McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
a. Hospital  staff includes nurses  (qualified  and nonqualified)  and medical technicians  for 1989. U.K. data  is for England  only. 
b. Exceeding over-the-counter  drugs for which prescriptions  are written. Figure 
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INPATIENT  FOCUS  OF  THE  DISEASES  STUDIED.  All three diseases  studied 
in Germany were frequently treated with surgery, and all required sig- 
nificant  inpatient  stays.  These  differences  in  treatment patterns may 
have  biased  our results  to  the  extent  that Germany's  greater use  of 
inputs relative  to the United  States was  concentrated  in surgeons  and 
hospital capacity.  It is therefore possible that a comparison of treatment 
processes for outpatient procedures, or for nonsurgical care, would have 
found smaller differences  in inputs between  the two countries. 
DATA  LIMITATIONS.  Although  we  do not think it is  a major factor, 
our input data did not  include  detailed  information  on  capital  costs. 
Because  they were less  than 10 percent of total cost  in all three coun- 
tries,  this omission  should not be a large issue,  but it could have led to 
some  discrepancy  in  aggregate  and disease-level  comparisons.  Ger- 
many's  supply  of  hospital  capacity  per capita far exceeded  the U.S. 
supply, despite higher occupancy levels  in Germany. The United States 
used more of some expensive  technologies,  such as CT and MRI (mag- 
netic resonance  imaging)  scanners. 
Relative  Input Prices 
The prices of many medical  inputs were higher in the United States 
than in either Germany or the United Kingdom.  Figure 9 shows average 
input prices in the three countries for physicians,  nurses, and prescrip- 
tions.38 The  most  striking differences  are in physician  incomes.  The 
U.S.  physicians  earned on average about twice  as much as physicians 
in Germany and about two-and-a-half  times  as much as physicians  in 
the United  Kingdom,  reflecting  both a higher wage  premium for phy- 
sicians  in the United  States relative to other professional  workers and 
somewhat  higher average wages  in the United States. 
The pattern of higher input prices  in the United  States corresponds 
to the structure of the three health care systems.  Both Germany and the 
United  Kingdom  featured  central  administration  of  their health  care 
financing systems.  Their governments and agencies  may therefore have 
acted like monopsony  buyers of medical services  and used their market 
power  to  drive  down  prices.  Although  the  United  States  had  some 
38.  These prices are converted to U.S.  dollars at GDP PPP (purchasing power parity) 
ratios  for  comparability.  This  price  comparison  methodology  is  consistent  with  our 
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Figure 9. Input Prices across the United States, Germany,  and the United Kingdom 
U.S. dollarsa 
PHYSICIAN  ANNUAL  SALARIES 
U.S.  164,000 
Germany  80 000 
NURSE  ANNUAL  SALARIES 
U.S.  33,300 
Germany  30,200 
UK 
U.K.~  21,600 
PHARMACEUTICAL  COST  PER PRESCRIPTION 
U.S.  22.40 
Germany  15.20 
UK  950 
Source: McKinsey Global Institute  and the McKinsey Health  Care  Practice  (1996). 
a. 1990 U.S. dollars,  adjusted  for purchasing  power parity. 194  Brookings  Papers: Microeconomics  1997 
market power  in purchasing  (mostly  through Medicare),  many  input 
prices  were  set  in  markets without  dominant buyers  but with  strong 
sellers.  Thus the relative concentration and market power of buyers and 
sellers of medical  services  in the three countries may have contributed 
to the observed  differences  in input prices.  In addition,  differences  in 
relative  provider  skill  or experience  levels  may  have  contributed  to 
observed  price  differences,  which  in turn could  have  contributed  to 
different productive efficiency  levels.  Furthermore, physician  incomes 
in  the  United  States  reflect  to  some  extent  the  significant  education 
costs  borne  directly  by  the  physician.  A  comprehensive  analysis  of 
pricing  levels,  their  causes,  and their  potential  effect  on  productive 
efficiency  was outside the scope  of our study. 
Relative Administrative Spending 
Administrative  spending  includes  four distinct  cost  categories  that 
are difficult  to  disaggregate:  (1)  payor,  provider,  and  government 
agency  costs  for administering  the insurance and provider reimburse- 
ment system;  (2)  provider costs  associated  with managing health care 
facilities  and practices; (3) payor costs for selling  and marketing health 
coverage  products to purchasers and members; and (4) payor and pro- 
vider costs for care management,  including utilization review and qual- 
ity  assurance.  We  combined  information  on  administrative  costs  in- 
curred by  payors  and hospitals  in the  three countries,  together  with 
suggestive  data from a U.S.-Canada  comparison study to estimate total 
administrative spending at 24 percent of total costs in the United States, 
13 percent in Germany,  and 16 percent in the United Kingdom.39 
Several factors may have contributed to higher administrative costs 
in the United States. For example,  the relative fragmentation of provid- 
ers and payors and the resulting complexity  of the insurance and reim- 
bursement system may have played a major role; a single-payor  system 
can simplify  the providers' interface with the reimbursement system by 
eliminating  much  of  the  claims  processing  and can  reduce  or  even 
eliminate  marketing and sales expenses. 
It is possible  that administrative costs  cannot be separated precisely 
39.  These  figures are rough calculations  and may be a slight  overestimate  because 
the hospital  administrative  cost  percentage  appears to be slightly  greater than the per- 
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from patient care. Higher administrative costs in the United States may 
have resulted from a more significant care management function on the 
part of payors and providers,  which  in turn could have contributed to 
the higher  U.S.  productive  efficiency  observed  in the disease  cases. 
There may be a trade-off between  productive efficiency  and the cost of 
running the system. 
The reasons  for studying  the disease  treatment on its own  are that 
we did not have administrative inputs by disease,  that we remain unsure 
of the validity  of our administrative cost  estimates  even  in the aggre- 
gate,  and that we have little evidence  about the size,  or even existence, 
of a trade-off between  administrative costs  and treatment costs.  As we 
discuss  later,  Germany and the United Kingdom  could  probably raise 
their  treatment  productivity  without  adding  much  to  administrative 
costs;  and the United  States is already finding ways  to cut such costs 
without changing the basic competitive  structure of the system,  notably 
through the proliferation of managed care. 
To see how sensitive  our results are, however,  one can make a crude 
adjustment for administrative  costs  by adding 24  percent,  13 percent 
and 16 percent,  respectively,  to the inputs in the three countries.  This 
adjustment would  leave  the productive  efficiency  advantage  with the 
United States for lung cancer and cholelithiasis,  although it would close 
the gaps (raising relative productivity by about 10 percent for Germany 
and 7 percent for the United Kingdom).  The breast cancer results would 
continue  to be ambiguous,  and the United  Kingdom  would  look  even 
stronger in diabetes. 
Decomposing  the Spending Differences 
To  help  understand the  aggregate  spending  numbers better and to 
judge the relative importance of the alternative reasons for the discrep- 
ancy between  these numbers and the case  studies,  we decomposed  the 
aggregate spending differences  into price, quantity, administration, and 
residual  factors.  The results  are shown  in figure  10. We  started with 
expenditures on physicians,  drugs, and hospitals.  We then broke these 
down  into the number of physicians  and their salaries,  the quantity of 
prescription drugs and average prices for drugs, and the number of bed- 
days and the price per bed-day.  The last category of hospital spending 
was  adjusted  for  the  higher  staffing  level  in  the United  States.  The Figure 
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component  of  per diem  charges  attributable to higher  staffing  in the 
United  States  was  counted  as a quantity,  not a price difference.  The 
administrative cost figures are based on the information discussed  ear- 
lier.40 Finally,  there  is  a residual,  or  "other,"  factor,  reflecting  the 
remaining  differences  in per capita  spending  that are not part of  the 
three  main  categories.  Examples  include  dental  care  and doctors' 
assistants. 
This  decomposition  is  necessarily  rough,  but it does  suggest  that 
price differences  make up the largest element  in explaining  the higher 
expenditure  in the United  States.  The  gap  in doctors'  salaries  alone 
accounts for 20 percent of the spending gap between  the United States 
and Germany and about 13 percent of the U.S.-U.K.  gap. 
On balance,  therefore,  we  believe  that the aggregate  numbers are 
consistent  with the results of the cases.  The higher rate of spending in 
the United  States is driven largely by higher prices and administrative 
costs.  Higher  disease  incidence  may  also  be  a  factor,  although  its 
importance  in  the  aggregate  was  not  something  we  could  estimate. 
Overall,  we judge  that the high  productivity  of  the U.S.  health care 
delivery  system works to offset  these other reasons for high health care 
costs. 
Recent and Future Changes in the Health Care 
Delivery Systems 
The results of the case studies come from the 1980s; since then there 
have been important changes in all three countries.  In the United States 
the largely market-based system is leading to greater competitive  inten- 
sity  and an increased  ability  to provide  integrated care,  even  without 
significant  regulatory  changes.  More  integrated and managed care is 
being provided by HMOs and preferred provider organizations.  These 
approaches have  grown  rapidly in importance as employers  have  de- 
manded lower cost health care coverage  for their employees. 
40.  Other adjustments were also made to the per diem hospital charges.  Daily  rates 
include payment for the administrative costs  of the hospital,  so we have tried to remove 
this part of  the payment  (so  as not to double-count  such costs).  We have  also  tried to 
adjust for that part of the hospital costs  paid for directly by governments. 198  Brookings  Papers: Microeconomics  1997 
Specialized  clinics  and more  aggressive  management  for  diabetic 
care have emerged,  including  an emphasis  on self-care,  as a result of 
actions on the part of integrated provider systems,  managed care payors, 
and manufacturers of  diabetic  supplies.  The benefits  of  such an inte- 
grated approach to care started to outweigh  the potential adverse selec- 
tion problem. Furthermore, "disease  management"  approaches to care 
as a way to manage costs  and improve outcomes  have grown in popu- 
larity among managed care organizations,  integrated provider systems, 
and suppliers. 
Not  surprisingly,  these  developments  have also  led to a decline  in 
compensation  for specialist  physicians  and to  actual price reductions 
for health coverage in some markets. The effects on administrative costs 
are unclear,  however.  Although  recent consolidations  among and be- 
tween  payors and providers have led to administrative cost decreases, 
there is some evidence  that the share of administrative costs focused  on 
care management (in the form of information systems,  personnel,  and 
so forth) have increased. These changes,  however,  may have improved 
productive efficiency. 
In the  United  Kingdom,  reforms  passed  in  1991  introduced  some 
competition  at the local level  between the payor function and providers 
through the  creation  of  an internal market,  fostered  somewhat  more 
integrated  care,  but  left  the  lifetime  payor  coverage  and monopoly 
power of the NHS largely intact. More decentralized health authorities 
were  given  the responsibility  of  purchasing  services  from competing 
providers; general practitioners were allowed to become  "fundholders'" 
and thereby assume  and manage the financial risk of  a broader set of 
care provision services  (such as drugs, outpatient care, diagnostic tests, 
and nonurgent  surgical  procedures);  and many NHS-owned  hospitals 
were effectively  privatized into self-governing  trusts. In addition, these 
hospital  trusts were given  greater control over their capital purchases, 
with funds loaned to them by the government with interest,  much like 
a commercial  transaction.  The  overall  budget and many other supply 
constraints remain,  however,  and efforts  to encourage  the use of non- 
public financing sources have met with little success. 
Although  these  system  changes  apparently have  not increased  ad- 
ministrative  costs,  their effects  on productive  efficiency  are still  un- 
clear.  As  many as 50,000  nursing jobs  and 60,000  hospital beds have 
been  eliminated  since  1990,  but 20,000  more  senior  managers  have Martin  Neil Baily and Alan M. Garber  199 
been  added in the NHS,  according  to some  estimates.4'  And there is 
some evidence  that adoption of technology  has quickened (for example, 
a targeted  breast cancer  screening  program based  on  mammography 
was established;  adoption of laparoscopic  technology  for cholecystec- 
tomy has neared U.S.  levels),  resulting from better NHS evaluation and 
fiat as well  as from increased provider responsiveness  to demand. It is 
also possible  that the general practitioner fundholders can now encour- 
age  and achieve  more rapid incremental  improvements  in health care 
delivery  by exerting  more direct pressure on local  specialists  and hos- 
pitals.  Although  some supply and capital constraints remain for hospi- 
tals and their associated  specialists,  and competition  has been limited 
outside the major metropolitan areas, we would expect  some improve- 
ment  in the  system's  productive  efficiency  over  time,  at least  in the 
diseases  studied. 
In Germany major reforms have been made in health coverage,  and 
to a lesser extent,  the care provision  markets. As of  1996 payors (sick- 
ness  funds) are allowed  to compete  for members on the basis of price 
and other  factors,  but restrictions  on  their ability  to  negotiate  price 
differentially  with  providers  or to  bundle  care  in different  ways  (by 
disease  or case,  for example)  have been left intact. Regulated case-rate 
payments for hospitals  have been introduced to substitute for per diem 
payments,  but they cover only  about 15 to 20 percent of cases.  Regu- 
latory barriers between  inpatient and outpatient care remain, as do the 
regulatory processes for controlling hospital and physician supply. Pay- 
ors are, not surprisingly,  searching actively  for and adopting the U.S. 
practices  for  managing  care  such  as  hospital  utilization  manage- 
ment-but  they face significant regulatory limitations in what they can 
implement.  Additional  reforms under discussion  for  1997 are focused 
on managing hospital costs through, for example,  the introduction of a 
regional-  or state-level  hospital budget. 
Recent changes  in the German system  are unlikely  to improve pro- 
ductive  efficiency  much,  unless  they  eventually  lead  to  removal  of 
regulatory constraints on inpatient and outpatient substitution,  greater 
flexibility  in payors' negotiations  with individual or groups of hospitals 
and physicians,  or to  the  widespread  adoption  of  case-rate  hospital 
payments. 
41.  Whitney,  Craig R.  1996.  "Health  Squeeze-A  Special  Report: Rising  Health 
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Conclusions 
The desire to limit  government  and private expenditures  for health 
care while  improving  health outcomes  makes health care productivity 
an important policy  issue throughout the world.  Although productivity 
is only  one  aspect  of  the performance of  any health care system,  im- 
provements  in productivity  can make it easier to achieve  other health 
system  goals,  such  as greater access  to care and protection  from the 
financial losses  resulting from ill health. 
For three of the four cases  examined  here the productive efficiency 
of the treatment delivery  part of the U.S.  health care system compared 
favorably with that of Germany and the United Kingdom.  The produc- 
tive efficiency  of the United States exceeded  that of Germany and was 
never clearly inferior to that of the United Kingdom.  Only in the man- 
agement  of diabetes,  a chronic disease  that can be treated better with 
the kind of integrated disease  management implemented  in the United 
Kingdom  in the  1980s,  did the United States fall behind. 
Patterns of care were consistent  with the incentives  and constraints 
operating in each system. The United States had the most heterogeneous 
system,  which during the late  1980s was characterized by fee-for-ser- 
vice reimbursement for health care, relatively  low levels  of integration 
of services,  a high degree of competition  among payors and providers, 
and relatively  few regulatory constraints on the organization of services 
and the acquisition  of new medical technologies. 
The United Kingdom's  governmental system of health care financing 
and delivery had a single payor and little or no direct competition among 
providers.  The  budgeting  system  used  to  reimburse providers  led  to 
constraints  on resources,  particularly for capital  acquisition,  with ef- 
fective  limitations  on overall expenditures for health care. The system 
was  relatively  well  positioned  to  implement  integrated programs for 
managing chronic  diseases  like diabetes,  yet underinvestment  in both 
new and old technologies  may have impaired productivity. 
The German system was substantially more regulated than that in the 
United  States,  with  little  flexibility  in  the  organization  of  services. 
Several  features,  such as rewards for longer hospital  stays,  served as 
disincentives  to increase overall productivity. 
Although  the case  studies  did not demonstrate that any single  form 
of organization  of care was associated  with uniformly greater produc- Martin  Neil Bailv and Alan M. Garber  201 
tivity,  we  believe  that they  strongly  suggest  that flexibility  in the or- 
ganization of care, coupled with competition  among providers and ap- 
propriate  incentives,  is  most  likely  to  promote  productivity  in  the 
treatment process.  The  unanswered  question  is  whether  and to  what 
extent  higher prices  and administrative  costs  are or are not results of 
this same flexible  and productive system  and hence offset  much of the 
productivity  advantage.  It remains to be seen whether the advantages 
of  the U.S.  health  care  system  can be  obtained  while  holding  down 
administrative  costs  and putting  appropriate competitive  pressure on 
prices.  It is also  unclear whether quality of  care will  deteriorate with 
declines  in the prices of individual or bundled health services.  Never- 
theless,  we believe  that recent trends, including improved measurement 
of  health  outcomes,  greater price  sensitivity  among  purchasers,  and 
various administrative efficiencies,  will help the United States improve 
overall  performance in health care in the coming  years. 
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neva. Comments 
Comment  by Ernst  R.  Berndt:  Martin Baily  and Alan  Garber seek 
answers to two very important and timely questions: First, what are the 
sources of the apparently very large differences  in health care spending 
among  industrialized  countries?  And second,  why  do those  spending 
differences  appear  to  be  unrelated  to  differences  in  overall  life 
expectancy? 
Rather than attempting to answer these two questions directly,  Baily 
and Garber examine the treatment costs and protocols for four relatively 
common diseases  or conditions  in three countries.  For each of the four, 
they  quantify  the total physical  inputs used  in treating a case  of  that 
disease,  the medical and quality-of-life  outcomes achieved by the health 
care sector in each country in treating that particular disease,  and, thus, 
the productive efficiency  or productivity  levels  realized by each of the 
three countries in treatments of these four diseases. 
This  approach to assessing  the sources  and consequences  of  varia- 
tions  in health care expenditures  across countries is extremely  useful, 
for it allows  the investigators to combine aggregate-level  analyses with 
disease-specific  details and considerations.  Moreover,  such a focus  on 
input,  output,  and outcomes  measurement at the level  of  specific  dis- 
eases  builds on an emerging health economics  literature.  ' The concep- 
tual framework employed by the authors envisages  disease treatment as 
a productive  process  involving  inputs and outputs and one  in which 
outputs can be positive  or negative. 
1.  See,  for example,  Cutler and others (1996);  Ellison and Hellerstein (1997);  Frank, 
Berndt, and Busch  (1997);  and Triplett (1997). 
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Figure  1. Productivity  Comparisons  among  Countries 
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Source:  Author's  calculations. 
The basic  idea is displayed  in figure  1, where  favorable  outcomes 
are on the vertical axis,  and an index of total input quantity per treated 
case is on the horizontal axis.  To establish productivity rankings, Baily 
and Garber undertake pairwise comparisons.  Relative to point A in the 
middle  of  the  figure,  we  see  that in the  northwest  quadrant, greater 
favorable  outcomes  are associated  with  fewer  total inputs per treated 
case  than at point A; thus all points  in this northwest quadrant unam- 
biguously  represent greater average productivity than at A.  The south- 
east  quadrant is  symmetric,  in  that relative  to  point  A,  points  here 
represent lower  average  productivity-favorable  outcomes  are fewer 
and total inputs per treated case  are larger. Without further structural 
information  on  the  shape  of  the  production  function,  however,  one 
cannot rank average  productivity  in the southwest  or northeast quad- 
rants relative  to point A,  for favorable  outcomes  are larger (smaller) 
and total  inputs per treated case  are larger (smaller)  in the northeast 
(southwest)  quadrant than at point A. 
To resolve such potentially ambiguous cases,  the authors assume that 
"the treatment of a given disease is fundamentally a diminishing returns Martin  Neil Baily and Alan M. Garber  205 
activity. " Under this assumption (and even under the weaker assump- 
tion of nonincreasing  returns), as long as a country or disease  lies on a 
point above (beneath) a 45-degree  line emanating from A, that country 
has greater (lesser)  productivity than A. 
The plausibility  of the assumption of global decreasing returns at the 
per-case  level  depends  on the empirical  validity  of  two  assumptions: 
that patients who  are most likely  to benefit are the first to be treated; 
and that the most cost-effective  treatments are the first to be used. 
It is useful  to consider  cases  where these assumptions  might not be 
valid.  If physicians  do not choose  which patients should be treated first 
(if triage is not operative),  but instead typically  treat those who present 
themselves  with symptoms and illnesses  with varying levels  of severity 
on a first-come,  first-served basis,  then the first assumption would not 
necessarily  hold.  Moreover,  for those medical illnesses  and conditions 
that are substantially  underdiagnosed,  there  is  no  a priori reason  to 
expect  a merit  ordering  of  severity  from  those  who  seek  treatment. 
Indeed,  as the authors hint when discussing  treatments for cancer pa- 
tients,  those beyond a reasonable chance of successful  treatment could 
in  many  cases  be  the  first to  present  themselves  for  diagnosis  and 
treatment. With respect to the second assumption, given issues of moral 
hazard, third-party payment,  and well-known  geographical  variations 
in medical  practice within  the United  States,  it is not at all clear that 
the most cost-effective  treatments are, in practice, the first to be used.2 
In short, the decreasing returns assumption is one that can plausibly be 
called  into question.  Fortunately,  in their empirical  work,  all that the 
authors need is the weaker assumption of nonincreasing returns to scale. 
Although relatively  straightforward conceptually,  the actual conduct 
of  this  empirical  research  effort  involved  enormous  resources;  Mc- 
Kinsey apparently had as many as twenty people working on this project 
over a three-year period.  This  is a massive  empirical  study.  Unfortu- 
nately, the sheer size and length of the study mean that when it is finally 
published,  it runs the danger of  being  already somewhat  out of  date. 
The data used are drawn from the mid- and late 1980s and are therefore 
already a decade old,  a rather long time in the rapidly changing health 
care marketplace.  Indeed, even the borders of the country of Germany 
have changed  since the data were collected. 
2.  See,  for example,  Wennberg  (1984)  and the studies  summarized in Folland  and 
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Figure 2. Summary  of Baily-Garber  Conclusions 
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Source:  Author's  calculations. 
Note: US is United States, UK is United Kingdom,  and G is (West) Germany.  LC refers to lung cancer, DB to diabetes, BC to 
breast  cancer,  and GS to gallstones. 
The Baily-Garber  conclusions  are summarized  in figure 2 here.  In 
that figure, when country A has productivity superior to that of country 
B,  the notation A >  B is employed.  As seen in the northwest quadrant 
of  figure  2,  in  four  instances  the  pairwise  country  comparisons  are 
unambiguous,  because A has fewer inputs per case and better outcomes 
than does B.  Assuming  nonincreasing  returns to scale,  five more rank- 
ings can be obtained; these appear in the southwest and northeast quad- 
rants.  Only  in one  case,  that involving  a comparison  of  productivity 
between  the United States and the United Kingdom in the treatment of 
breast cancer,  is it impossible  to reach a definitive  conclusion  without 
further information.  Even here, however,  considerations  of cost effec- 
tiveness  employed  by the authors enable them to rank the U.S.  produc- 
tivity higher than that of the United Kingdom. 
What are the sources  of  these differences?  David  Cutler elaborates 
more on these differences  in his comments,  but let me briefly state that 
relative to Germany, the United States tends to employ more outpatient 
and less  inpatient days of services,  and conditional  on hospitalization, Martin  Neil Bailv and Alan M. Garber  207 
average  length of  stay is shorter in the United  States.  Relative  to the 
United  Kingdom,  the  United  States  has  been  quicker  to  adopt  such 
high-tech  medical  products and procedures as CT scanners and lapa- 
roscopic  surgery,  but its (until recently)  more fragmented health care 
system  has  not taken as much advantage  of  team provider processes 
such as those  involved  in the United Kingdom's  treatment of diabetes. 
Baily-Garber  use  QALYs  (quality-adjusted  life  years)  in the  gall- 
stone and diabetes outcomes  measurements,  but not for breast and lung 
cancers.  Survival rates for patients with lung cancer are very low,  and 
neglect  of QALYs  is a defensible  research strategy.  For breast cancer, 
however,  five-year  survival  rates in the United  States are currently at 
least  50  percent  and rising,  and thus the  a priori case  for excluding 
QALYs  is  not very  strong  and one  I am sure that patient advocacy 
groups would  vigorously  challenge.  Quality-of-life  adjustments could 
be quite significant  in the treatment of breast cancer.  Substantial prog- 
ress  has been  achieved,  for example,  in making chemotherapy  treat- 
ments for breast cancer less burdensome for patients; recent noteworthy 
biotech and pharmaceutical product innovations reduce discomfort from 
nausea, leave patients less vulnerable to infections,  and increase energy 
levels  by reducing anemia. There may well be differences  across coun- 
tries in the use of such products. 
Finally,  the medical community has learned in the last few years that 
a very substantial proportion of  women  diagnosed  with breast cancer 
experience  depressive  episodes  during treatment, a condition  that ap- 
parently  has  been  considerably  underdiagnosed.  How  treatment  of 
breast cancer deals with associated comorbid conditions such as depres- 
sion is a topic of considerable  importance in interpreting international 
differences  in treatment costs  and quality-of-life-adjusted  outcomes. 
Thus the a priori case for including QALYs when comparing outcomes 
of treatment for breast cancer across countries is a rather plausible one. 
As the authors note,  quality-of-life  data associated  with the treatment 
of both breast and lung cancer apparently were not available when the 
data were collected.3 
The Baily-Garber  study is a massive  one tackling  a very important 
set of issues,  but many issues  remain to be explored.  Two are particu- 
3.  There is,  however,  a substantial  literature on the measurement of  quality of  life 
in cancer patients.  See,  for example,  Barofsky (1996),  Goodyear and Fraumeni (1996), 
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larly interesting.  First,  it is well  known that within the United  States 
(as  well  as  in  other countries),  there  is  a tremendous  diversity  and 
variation  among  hospitals  and physicians  in  treatment protocols  for 
particular diseases,  illnesses,  and conditions.4  Although  the existence 
of the National Health Service  in the United Kingdom might facilitate 
greater uniformity  in treatments,  and although Baily  and Garber have 
undertaken a thorough  analysis  involving  numerous  interviews  with 
clinicians  and health care administrators,  I would  have  liked  to have 
seen at least a bit more discussion  on literature dealing with the size of 
within-country  variation relative to between-country  variation. 
Second,  it  is  also  well  known  in health  economics  that for  many 
medical  expenditure  categories,  the  mean  treatment  expenditure  is 
much larger than the median, because of the existence  of a far right tail 
reflecting  relatively  small numbers of extremely  high-cost  or high ex- 
penditure cases.  In this  paper Baily  and Garber examine  means  and 
compare  means  across  countries.  An  alternative  approach would  in- 
volve  focusing  on the outliers  how do treatments of the very rare but 
costly  cases differ across countries? Focusing on the extreme high-cost 
cases  may have just as large an effect  on explaining  differences  in total 
costs  per case  across countries as does a focus  on the most representa- 
tive or median treatments. 
Baily  and Garber conclude  by providing four useful  facts regarding 
the apparent "big  picture"  paradox of unproductive medical expendi- 
tures in the United  States.  First,  for each  of  these  four diseases,  the 
United States has a higher incidence  than either the United Kingdom or 
Germany.  Why that is the case  is not clear,  nor is it clear whether this 
generalizes  to  other diseases  or conditions.  Are we  Americans  more 
disease  prone? Or has our insurance system with all its principal-agent 
incentive distortions yielded greater amounts of diagnosed illnesses  per 
capita? 
Second,  at least in the mid- and late 1980s,  the factors of production 
in health care were all higher priced in the United States.  Recent work 
suggests  that at least initially the impact of managed care in the United 
States on treatments of certain conditions  has involved  greater reduc- 
tions of prices than of treatment quantities.5 To the extent this is true, 
4.  See  Wennberg (1984)  and Folland and Stano (1990)  for further discussion. 
5.  Cutler,  McClellan,  and Newhouse  (1997);  Berndt, Frank, and McGuire (1997). Martin  Neil Baily and Alan M. Garber  209 
the  expenditure  differences  among  the  three countries  in  the  period 
observed by the Baily-Garber study may well be decreasing as managed 
care diffuses  more fully  in the United States. 
Third, the Baily-Garber study excludes  administrative costs,  which 
they estimate  to be 24  percent of  total costs  in the United  States,  16 
percent in the United Kingdom,  and only  13 percent in Germany. What 
the influence of managed care will be on administrative costs  is not yet 
clear,  particularly because  cost-reducing  developments  in information 
technology  would  appear to give  particularly large cost  advantages to 
centrally administered single  payor systems,  such as that in the United 
Kingdom. 
Fourth and finally,  and now  in the context  of aggregate data rather 
than disease-specific  cases,  aggregate  life  expectancy  appears to  be 
affected  quite  critically  by  neonatal  mortality,  which  is  worse  in the 
United  States.  Differences  among countries  in life  expectancy  condi- 
tional on surviving  to a threshold year are considerably  smaller.  This 
leads Baily and Garber to put one red herring to rest for good: "Overall 
life  expectancy  at  birth  .  .  .  may  be  an  unsuitable  measure  of  health 
outcomes for the purpose of measuring productivity of health services. 
That is a simple but important message  well  worth remembering. 
Comment  by David  M.  Cutler:  This paper is an extremely  nice  look 
at a very difficult question.  Measuring the productivity of the medical 
care system is hard enough; comparing productivity across countries is 
even  more difficult.  Yet  that is the task of  the paper. Some  evidence 
on the sheer magnitude of the work involved  comes  from knowing  that 
the longer  study on which  this summary is based is two inches  thick, 
and the  list  of  McKinsey  personnel  involved  in the study  is  perhaps 
twenty lines  of very dense text. 
The  methodology  of  the paper is to compare productivity  for four 
conditions  in the United States, the United Kingdom,  and Germany and 
then to try to generalize  from these cases.  This seems exactly  the right 
approach. Productivity  comparisons  of the medical  system  as a whole 
are just  too  difficult  to  be  of  much  use  in  this  market.  To  compare 
medical  care productivity  across  countries,  one  must look  at a more 
detailed level. 
The paper concludes  that with few exceptions,  the United States is 
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many. Because  the paper measures average productivity,  not marginal 
productivity,  this  conclusion  does  not  seem  too  surprising.  But at a 
closer  look,  the results are quite surprising.  Consider what is conven- 
tionally thought to be a description of the U.S.  medical care system: If 
you  are fortunate to  be well  insured,  the medical  care system  in the 
United States is the best in the world. The care is lavish,  the technology 
is sophisticated,  and the doctors  are the best.  Outcomes  are better in 
the United  States than elsewhere.  But you pay a lot for this.  For most 
people,  the additional care is worth it. Some people,  however,  get much 
more  care  than  is  appropriate.  At  the  margin,  therefore,  there  is  a 
substantial waste of resources. 
This  is  not  what  this  paper finds.  Although  there  are differences 
across diseases,  consider  the paper's analysis  of productivity  for cho- 
lelithiasis  (gallstones).  For patients  who  receive  surgery,  inputs  are 
substantially  less  in the United  States than in the other two countries. 
Some of this is due to technology;  laparoscopic cholecystectomy  (a less 
invasive  form  of  surgery than the traditional open  cholecystectomy) 
diffused  much more rapidly in the United  States than in either of  the 
other two  countries.  But  in  some  cases,  the  United  States  also  uses 
fewer  inputs  for a given  procedure,  and hospital  stays  in the United 
States are far shorter than they are in the other two  countries.  On the 
outputs side,  the rate of surgical complications  is essentially  the same 
across countries.  The net effect  is that the United  States is more pro- 
ductive than either the United Kingdom or Germany, but the difference 
is entirely  on the input side.  Outputs per treatment are the same; the 
United States just provides those treatments with fewer resources. 
Although  there are certainly  differences  across diseases,  the domi- 
nant conclusion  of  the Baily-Garber  study is  that most of  the United 
States's  higher  productivity  is  because  the medical  care  system  uses 
fewer  inputs,  such as shorter hospital  stays and more outpatient care. 
Outcome differences  are much smaller across countries,  and for some 
diseases,  output conditional  on treatment is the same across countries. 
This finding is very different from the conventional  wisdom.  In my 
comments  I want to bridge the gap between  the findings in this paper 
and the conventional  wisdom  and then offer a few comments about the 
definition of productivity.  I shall mix thoughts about the current paper 
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Incorporating  Morbidity 
The most difficult issue in the paper is the measurement of outcomes. 
For breast cancer and lung cancer,  the authors use survival to measure 
outcomes.  This makes good  sense;  for a patient with cancer,  survival 
is almost everything.  For the nonfatal conditions  (diabetes  and chole- 
lithiasis),  however,  the authors do not have particularly good measures 
of outcomes.  For cholelithiasis,  there is essentially  no measure of mor- 
bidity  (other than surgical  complications,  which  are the  same  across 
countries).  And for diabetes,  the authors use data on some  complica- 
tions,  but the most life-threatening  complications  (end stage renal dis- 
ease,  ischemic  heart disease,  and stroke) cannot be isolated well enough 
to be incorporated.  In addition,  there is no analysis  of morbidity con- 
ditional on the level  of complications. 
The lack of good morbidity data for nonfatal illness  is crucial. If one 
asks what a very intensive  medical care system  is likely to provide for 
a generally  nonfatal illness,  the answer is twofold:  more sophisticated 
techniques  to improve quality of life; and a greater chance of detecting 
very rare complications.  The first of these  is essentially  ruled out be- 
cause  the  authors cannot  measure  it.  The  second  is  likely  to  be  too 
difficult  to detect  without  a much larger sample  of  patients.  Thus,  it 
seems  to me that the paper systematically  undercounts morbidity ben- 
efits from very  intensive  medical  practice.  Because  the United  States 
has the most technology-intensive  medical system,  I suspect the paper 
systematically  undercounts health outcomes  in the United States. 
Indeed,  it is striking that for lung and breast cancer,  outcomes  con- 
ditional on treatment are generally better in the United States than they 
are in other countries,  but that is not true for the nonfatal conditions. 
This may be because the appropriate morbidity data is not there to allow 
this comparison. 
Raising the issue of better outcome measures is fine, but what should 
be done  about it? It seems  to me that a different  sampling  method is 
required from the one the authors use.  The authors measure outcomes 
by using cross-section  data where it is available.  For example,  compli- 
cation rates for diabetes  in the United States and the United Kingdom 
are based on the number of hospital admissions  for particular compli- 
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of hospital admissions  cannot be measured accurately,  there is no way 
to measure morbidity. 
An alternative estimation  strategy would be to sample patients with 
diabetes  in different  countries  and follow  these  patients over  time  to 
determine whether they experience  any adverse events.  In some cases, 
the  longitudinal  samples  have  already been  drawn (for example,  the 
Framingham Heart Study on cardiovascular disease);  indeed, this is the 
type of  data the authors use for cancer.  In other cases,  one could  get 
insurance records for people  with  a particular condition  and monitor 
their disease  progress over time. 
Using  a longitudinal  sample from insurance records or other sources 
would have two additional advantages.  First, it would allow the authors 
to adjust more accurately for the severity  of disease  across countries. 
For example,  in claims  records  one  can  find out  about the  patient's 
entire medical  record and thus construct an estimate of comorbid con- 
ditions.  Baily  and Garber generally  wind  up  assuming  that disease 
severity is the same across countries.  Second,  when patients have been 
ranked by severity,  the authors could look at how patients with different 
levels  of severity  fare in different countries. 
I suspect the lack of morbidity data is sufficiently  large that it skews 
the outcome measures for the nonfatal diseases quite severely.  My guess 
is that outcomes  for the nonfatal conditions  and even  for the poten- 
tially  fatal ones  are better in the United  States relative  to the other 
countries than the paper suggests.  But documenting this issue one way 
or the other will  require a different approach to the problem than what 
the authors have chosen. 
Input Differences  across  Countries 
Perhaps the most consistent  finding in the paper is that the United 
States  uses  substantially  fewer  inputs per medical  treatment than do 
other countries.  As noted earlier,  most of the productivity differences 
across the three countries come from the level  of inputs used.  Some of 
these differences  are clearly present and are important. The higher use 
of  laparoscopic  surgery  in gallstone  cases  in the United  States  is  an 
example. 
But many more of the differences  are in the length of hospital  stay 
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true in the comparison of the United States and Germany (where length 
of hospital  stays are much greater).  I am less  convinced  of the degree 
of  resource  savings  than are the authors. The important issue  is  how 
much hospital care is provided in the marginal day of care in Germany, 
and how many of  these  resources  wind up being provided at home or 
in outpatient  settings  in the United  States.  For many surgical  proce- 
dures, the last days of hospital care are relatively unintensive: monitor- 
ing  the patient or controlling  pain that could  be  done  in nonhospital 
settings. 
To be sure, some  additional resources are used in the hospital com- 
pared with outpatient settings,  but the resources are less than those used 
on an average day.  Although  the days in the hospital are adjusted for 
the average intensity of services  provided,  mismeasurement of average 
service  use is a concern.  As a result,  shorter hospital stays might gen- 
erate more (or less) apparent resource savings than are actually realized. 
Anecdotal  evidence  from managed  care and hospital  executives  sug- 
gests  that marginal services  provided in the last few  hospital days are 
not particularly large.  Many managed care insurers have  learned that 
the dollar savings  they realized  from reducing hospital  stays were not 
particularly large. Because shorter lengths of hospital stays are virtually 
the entire reason why  the United  States is more productive than Ger- 
many,  some caution about this conclusion  is appropriate. 
This  factor  and the  previous  one  may  offset  each  other,  and the 
United  States  may well  be more productive  than the other countries. 
But  I suspect  the paper probably  overstates  the resource  differences 
across countries  and understates the outcome  differences  in a way that 
affects the conclusions  about why productivity differs across countries. 
Productivity  Measurement 
The  final  issue  I  want  to  address  is  the  concept  of  productivity, 
particularly the authors' focus on average productivity across countries. 
International comparisons of medical systems raise two issues.  First, is 
one  country  better on  average  than another? This  is the question  the 
paper answers.  Second,  are the resources  being  put into the medical 
system  at the margin worth their cost?  This answer may differ across 
countries; in the United States,  my guess is the answer is "no."  When 
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that spending  can be  cut by  a significant  amount without  substantial 
adverse effects.  This is consistent with a low marginal value to medical 
services. 
This issue  has important implications  for the conclusions  of the pa- 
per.  Baily  and Garber summarize  their conclusions  as  "competition 
promotes  high  productivity."  I would  revise  the statement to  "com- 
petition promotes high average productivity  but low  marginal produc- 
tivity."  I suspect  the ranking of countries  is not nearly as obvious  as 
the paper suggests. 
The  Baily-Garber  paper,  and the McKinsey  study behind  it,  are a 
major advance in the understanding of the productivity of the medical 
system.  They conclude  that the United States is the most productive of 
the three countries  they analyze.  I suspect they are right. But I would 
guess  that there is  more to the conventional  wisdom  than the results 
indicate.  On the basis of this paper, one would conclude  that produc- 
tivity  is  high  in  the United  States  because  fewer  inputs  are used  to 
produce the same output. My sense is that productivity is higher because 
the United States achieves  greater outputs than the other two countries 
with the same or more inputs. To examine these questions,  economists 
will  need to make use of longitudinal data that the Baily-Garber paper 
does  not use.  Much work remains to be done. 
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